asafd60/LiLT_Processed · Datasets at Hugging Face

id string	words list	boxes list	question string	answer string
539	[ "Actos", "Pediatric", "Working", "Group", "Date:", "20", "April", "2006", "Time:", "4:00pm", "-", "5:00pm", "Meeting", "Minutes", "Place:", "Meeting", "Room", "403", "Attendees", "Attendees", "Alfonso", "Perez", "-", "Clinical", "Karen", "Kaluzny", "-", "Project...	[ [ 57, 76, 111, 92 ], [ 114, 77, 197, 92 ], [ 200, 76, 279, 93 ], [ 282, 76, 341, 93 ], [ 410, 76, 460, 91 ], [ 462, 77, 487, 91 ], [ 489, 77, 537, 91 ], [ 539, 76, ...	what is the place mentioned ?	Meeting Room 403
543	[ "Ms.", "Wakamatsu,", "Assistant", "manager,", "Dept.", "Strategic", "Development,", "et", "al.", "Attachment:", "NDA", "schedule", "for", "each", "project", "approved", "on", "the", "5th", "GDC", "1.", "Openings", "Remarks", "Dr.", "Kitazawa", "made", "opening", ...	[ [ 107, 142, 132, 152 ], [ 134, 142, 218, 152 ], [ 220, 142, 280, 153 ], [ 282, 142, 346, 153 ], [ 348, 142, 385, 153 ], [ 387, 142, 446, 153 ], [ 448, 141, 540, 153 ], [ 54...	Why was it suggested to prepare non-clinical "White paper"?	to address the bladder issue
539	[ "Actos", "Pediatric", "Working", "Group", "Date:", "20", "April", "2006", "Time:", "4:00pm", "-", "5:00pm", "Meeting", "Minutes", "Place:", "Meeting", "Room", "403", "Attendees", "Attendees", "Alfonso", "Perez", "-", "Clinical", "Karen", "Kaluzny", "-", "Project...	[ [ 57, 76, 111, 92 ], [ 114, 77, 197, 92 ], [ 200, 76, 279, 93 ], [ 282, 76, 341, 93 ], [ 410, 76, 460, 91 ], [ 462, 77, 487, 91 ], [ 489, 77, 537, 91 ], [ 539, 76, ...	who will forward the article regarding rosiglitazone and non clinical bladder data to andy ?	Mondira
539	[ "Actos", "Pediatric", "Working", "Group", "Date:", "20", "April", "2006", "Time:", "4:00pm", "-", "5:00pm", "Meeting", "Minutes", "Place:", "Meeting", "Room", "403", "Attendees", "Attendees", "Alfonso", "Perez", "-", "Clinical", "Karen", "Kaluzny", "-", "Project...	[ [ 57, 76, 111, 92 ], [ 114, 77, 197, 92 ], [ 200, 76, 279, 93 ], [ 282, 76, 341, 93 ], [ 410, 76, 460, 91 ], [ 462, 77, 487, 91 ], [ 489, 77, 537, 91 ], [ 539, 76, ...	What date is the meeting scheduled to develop the overall structure of the document?	in early May
540	[ "ACTOS", "FDA", "Response", "Meeting", "August", "12-13,", "2002", "Page", "4", "of", "4", "Highlights", "from", "Cohen", "Hypothesis", "Discussion", ">", "Philip", "Collett", "presented", "an", "outline", "of", "the", "Cohen", "hypothesis", "Male", "rat", "ur...	[ [ 654, 43, 693, 55 ], [ 695, 43, 720, 54 ], [ 722, 43, 777, 54 ], [ 780, 44, 824, 55 ], [ 713, 55, 754, 65 ], [ 757, 55, 795, 65 ], [ 797, 55, 825, 65 ], [ 760, 66, ...	Who presented an outline of the Cohen hypothesis?	Philip Collett
540	[ "ACTOS", "FDA", "Response", "Meeting", "August", "12-13,", "2002", "Page", "4", "of", "4", "Highlights", "from", "Cohen", "Hypothesis", "Discussion", ">", "Philip", "Collett", "presented", "an", "outline", "of", "the", "Cohen", "hypothesis", "Male", "rat", "ur...	[ [ 654, 43, 693, 55 ], [ 695, 43, 720, 54 ], [ 722, 43, 777, 54 ], [ 780, 44, 824, 55 ], [ 713, 55, 754, 65 ], [ 757, 55, 795, 65 ], [ 797, 55, 825, 65 ], [ 760, 66, ...	What is significant in the development of calculi?	Raising the pH of male rat urine above 6.5
540	[ "ACTOS", "FDA", "Response", "Meeting", "August", "12-13,", "2002", "Page", "4", "of", "4", "Highlights", "from", "Cohen", "Hypothesis", "Discussion", ">", "Philip", "Collett", "presented", "an", "outline", "of", "the", "Cohen", "hypothesis", "Male", "rat", "ur...	[ [ 654, 43, 693, 55 ], [ 695, 43, 720, 54 ], [ 722, 43, 777, 54 ], [ 780, 44, 824, 55 ], [ 713, 55, 754, 65 ], [ 757, 55, 795, 65 ], [ 797, 55, 825, 65 ], [ 760, 66, ...	What is the correlation observed in cohen's paper?	0.61
540	[ "ACTOS", "FDA", "Response", "Meeting", "August", "12-13,", "2002", "Page", "4", "of", "4", "Highlights", "from", "Cohen", "Hypothesis", "Discussion", ">", "Philip", "Collett", "presented", "an", "outline", "of", "the", "Cohen", "hypothesis", "Male", "rat", "ur...	[ [ 654, 43, 693, 55 ], [ 695, 43, 720, 54 ], [ 722, 43, 777, 54 ], [ 780, 44, 824, 55 ], [ 713, 55, 754, 65 ], [ 757, 55, 795, 65 ], [ 797, 55, 825, 65 ], [ 760, 66, ...	Why didn't rats eliminate calculi as humans do?	Because rats are quadropeds
547	[ "Minutes", "from", "Takeda", "Global", "Risk", "Management", "Forum/March", "22,", "2004", "Facilitators:", "Glyn", "Belcher,", "MA,", "PhD,", "MB,", "BCHIR,", "FFPM/", "TEuRD", "Cal", "McNeill,", "MD/", "TGRD", "Attendees:", "Mondira", "Bhattacharya", "MD,", "Dav...	[ [ 214, 145, 282, 159 ], [ 285, 145, 322, 160 ], [ 332, 145, 392, 160 ], [ 395, 145, 450, 161 ], [ 454, 145, 491, 161 ], [ 494, 144, 603, 161 ], [ 606, 144, 722, 160 ], [ 72...	What is the fullform of MAA?	Marketing Authorization Application
547	[ "Minutes", "from", "Takeda", "Global", "Risk", "Management", "Forum/March", "22,", "2004", "Facilitators:", "Glyn", "Belcher,", "MA,", "PhD,", "MB,", "BCHIR,", "FFPM/", "TEuRD", "Cal", "McNeill,", "MD/", "TGRD", "Attendees:", "Mondira", "Bhattacharya", "MD,", "Dav...	[ [ 214, 145, 282, 159 ], [ 285, 145, 322, 160 ], [ 332, 145, 392, 160 ], [ 395, 145, 450, 161 ], [ 454, 145, 491, 161 ], [ 494, 144, 603, 161 ], [ 606, 144, 722, 160 ], [ 72...	Which forum is mentioned in this document?	Takeda Global Risk Management Forum
542	[ "107", "FDA", "Conference", "Call:", "August", "13,", "2002", "PENGAD", "800-631-698", "EXHIBIT", "FDA", "Personnel:", "Jeri", "El-Hage,", "Ph.D.,", "Toxicology", "Team", "Leader", "Jena", "Weber,", "Project", "Manager", "TPNA", "Personnel:", "David", "Baron,", "P...	[ [ 785, 93, 849, 115 ], [ 170, 120, 206, 133 ], [ 211, 120, 304, 134 ], [ 307, 120, 350, 135 ], [ 355, 120, 413, 135 ], [ 417, 120, 440, 135 ], [ 442, 119, 481, 135 ], [ 728...	What is the issued date of this document?	august 13, 2002
542	[ "107", "FDA", "Conference", "Call:", "August", "13,", "2002", "PENGAD", "800-631-698", "EXHIBIT", "FDA", "Personnel:", "Jeri", "El-Hage,", "Ph.D.,", "Toxicology", "Team", "Leader", "Jena", "Weber,", "Project", "Manager", "TPNA", "Personnel:", "David", "Baron,", "P...	[ [ 785, 93, 849, 115 ], [ 170, 120, 206, 133 ], [ 211, 120, 304, 134 ], [ 307, 120, 350, 135 ], [ 355, 120, 413, 135 ], [ 417, 120, 440, 135 ], [ 442, 119, 481, 135 ], [ 728...	Who is the Director of Nonclinical Safety and Efficacy?	David baron
542	[ "107", "FDA", "Conference", "Call:", "August", "13,", "2002", "PENGAD", "800-631-698", "EXHIBIT", "FDA", "Personnel:", "Jeri", "El-Hage,", "Ph.D.,", "Toxicology", "Team", "Leader", "Jena", "Weber,", "Project", "Manager", "TPNA", "Personnel:", "David", "Baron,", "P...	[ [ 785, 93, 849, 115 ], [ 170, 120, 206, 133 ], [ 211, 120, 304, 134 ], [ 307, 120, 350, 135 ], [ 355, 120, 413, 135 ], [ 417, 120, 440, 135 ], [ 442, 119, 481, 135 ], [ 728...	Who described tumor promoter-model study?	dr. el-hage
542	[ "107", "FDA", "Conference", "Call:", "August", "13,", "2002", "PENGAD", "800-631-698", "EXHIBIT", "FDA", "Personnel:", "Jeri", "El-Hage,", "Ph.D.,", "Toxicology", "Team", "Leader", "Jena", "Weber,", "Project", "Manager", "TPNA", "Personnel:", "David", "Baron,", "P...	[ [ 785, 93, 849, 115 ], [ 170, 120, 206, 133 ], [ 211, 120, 304, 134 ], [ 307, 120, 350, 135 ], [ 355, 120, 413, 135 ], [ 417, 120, 440, 135 ], [ 442, 119, 481, 135 ], [ 728...	What is the duration of daily dosing?	32-weeks
541	[ "ACTOS", "FDA", "Response", "Meeting", "August", "12-13,", "2002", "Page", "2", "of", "4", "Summary", "of", "July", "31", "Teleconference", "with", "FDA", "(J.", "Haskins)", "-", "Continued", ">", "The", "group", "summarized", "the", "FDA's", "concerns", "as...	[ [ 654, 43, 692, 55 ], [ 695, 43, 720, 54 ], [ 722, 43, 777, 54 ], [ 780, 44, 824, 55 ], [ 714, 55, 754, 66 ], [ 757, 55, 794, 65 ], [ 797, 55, 824, 65 ], [ 760, 66, ...	Who updated the CEO on August 6?	Mr. Saito
541	[ "ACTOS", "FDA", "Response", "Meeting", "August", "12-13,", "2002", "Page", "2", "of", "4", "Summary", "of", "July", "31", "Teleconference", "with", "FDA", "(J.", "Haskins)", "-", "Continued", ">", "The", "group", "summarized", "the", "FDA's", "concerns", "as...	[ [ 654, 43, 692, 55 ], [ 695, 43, 720, 54 ], [ 722, 43, 777, 54 ], [ 780, 44, 824, 55 ], [ 714, 55, 754, 66 ], [ 757, 55, 794, 65 ], [ 797, 55, 824, 65 ], [ 760, 66, ...	By when should TPNA send outline of response to TCI ?	August 19
541	[ "ACTOS", "FDA", "Response", "Meeting", "August", "12-13,", "2002", "Page", "2", "of", "4", "Summary", "of", "July", "31", "Teleconference", "with", "FDA", "(J.", "Haskins)", "-", "Continued", ">", "The", "group", "summarized", "the", "FDA's", "concerns", "as...	[ [ 654, 43, 692, 55 ], [ 695, 43, 720, 54 ], [ 722, 43, 777, 54 ], [ 780, 44, 824, 55 ], [ 714, 55, 754, 66 ], [ 757, 55, 794, 65 ], [ 797, 55, 824, 65 ], [ 760, 66, ...	When will Mr. Saito present outline to CEO?	August 20
541	[ "ACTOS", "FDA", "Response", "Meeting", "August", "12-13,", "2002", "Page", "2", "of", "4", "Summary", "of", "July", "31", "Teleconference", "with", "FDA", "(J.", "Haskins)", "-", "Continued", ">", "The", "group", "summarized", "the", "FDA's", "concerns", "as...	[ [ 654, 43, 692, 55 ], [ 695, 43, 720, 54 ], [ 722, 43, 777, 54 ], [ 780, 44, 824, 55 ], [ 714, 55, 754, 66 ], [ 757, 55, 794, 65 ], [ 797, 55, 824, 65 ], [ 760, 66, ...	By when will the document be finalized?	August 26
545	[ "PENGAD", "BOO-631-698", "EXHIBIT", "102", "FDA", "Conference", "Call", "on", "July", "31,", "2002", "TPNA", "Personnel:", "Wendell", "Cheatham,", "M.D.", "Vice", "President,", "of", "Medial", "and", "Scientific", "Affairs", "Michael", "Elisseou,", "Ph.D.,", "Dire...	[ [ 814, 80, 828, 107 ], [ 815, 45, 830, 79 ], [ 868, 41, 919, 53 ], [ 874, 63, 928, 88 ], [ 344, 134, 382, 150 ], [ 385, 134, 474, 150 ], [ 478, 135, 510, 150 ], [ 514, ...	When will the FDA Conference Call be held?	July 31, 2002
548	[ "Task", "Notes", "Lead", "Responsibility", "Due", "Date", "8.", "COMPETITIVE", "INTELLIGENCE", "Update", "team", "on", "competitive", "Wendell", "Cheatham", "intelligence", "To", "Ongoing", "-", "update", "provided", "at", "each", "meeting", "9.", "Q&", "A", "SH...	[ [ 174, 100, 206, 113 ], [ 386, 101, 438, 114 ], [ 536, 101, 576, 115 ], [ 580, 101, 704, 116 ], [ 769, 101, 807, 115 ], [ 810, 101, 849, 115 ], [ 89, 122, 104, 135 ], [ 107...	When was this document last updated?	August 1, 2002
548	[ "Task", "Notes", "Lead", "Responsibility", "Due", "Date", "8.", "COMPETITIVE", "INTELLIGENCE", "Update", "team", "on", "competitive", "Wendell", "Cheatham", "intelligence", "To", "Ongoing", "-", "update", "provided", "at", "each", "meeting", "9.", "Q&", "A", "SH...	[ [ 174, 100, 206, 113 ], [ 386, 101, 438, 114 ], [ 536, 101, 576, 115 ], [ 580, 101, 704, 116 ], [ 769, 101, 807, 115 ], [ 810, 101, 849, 115 ], [ 89, 122, 104, 135 ], [ 107...	What is the last point in the table?	Evaluate Impact on Tak-559
548	[ "Task", "Notes", "Lead", "Responsibility", "Due", "Date", "8.", "COMPETITIVE", "INTELLIGENCE", "Update", "team", "on", "competitive", "Wendell", "Cheatham", "intelligence", "To", "Ongoing", "-", "update", "provided", "at", "each", "meeting", "9.", "Q&", "A", "SH...	[ [ 174, 100, 206, 113 ], [ 386, 101, 438, 114 ], [ 536, 101, 576, 115 ], [ 580, 101, 704, 116 ], [ 769, 101, 807, 115 ], [ 810, 101, 849, 115 ], [ 89, 122, 104, 135 ], [ 107...	What is the Draft's Due Date?	August 5
501	[ "Dr.", "Tan", "January", "14,", "1999", "Page", "5", "ELI", "LILLY", "AND", "COMPANY", "COMPENSATION", "AND", "BENEFITS", "PROGRAM", "(CONTINUED)", "Additional", "Company", "Benefits", "Medical", "and", "Dental", "Insurance", "Prescription", "Drug", "Benefits", "R...	[ [ 146, 110, 174, 124 ], [ 176, 111, 204, 124 ], [ 146, 126, 207, 140 ], [ 211, 126, 235, 140 ], [ 238, 126, 276, 139 ], [ 146, 143, 184, 156 ], [ 188, 143, 196, 156 ], [ 35...	Which benefit start after 1 year of service?	Extended Disability
543	[ "Ms.", "Wakamatsu,", "Assistant", "manager,", "Dept.", "Strategic", "Development,", "et", "al.", "Attachment:", "NDA", "schedule", "for", "each", "project", "approved", "on", "the", "5th", "GDC", "1.", "Openings", "Remarks", "Dr.", "Kitazawa", "made", "opening", ...	[ [ 107, 142, 132, 152 ], [ 134, 142, 218, 152 ], [ 220, 142, 280, 153 ], [ 282, 142, 346, 153 ], [ 348, 142, 385, 153 ], [ 387, 142, 446, 153 ], [ 448, 141, 540, 153 ], [ 54...	What is Ms Wakamatsu's role in Dept. Strategic Development?	Assistant manager
526	[ "08/07/2002", "18:47", "06", "6204", "2244", ".", "2002'", "08/08", "21:50", "FAX", "06", "6204", "2244", "TAKEDA", "DEVELOP", "DIVISION", "2", "006/006", "6", "/", "6", "Discussion", "points", "to", "address", "the", "three", "key", "issues", "raised", "b...	[ [ 58, 11, 152, 21 ], [ 181, 10, 228, 21 ], [ 272, 10, 291, 21 ], [ 299, 10, 339, 21 ], [ 346, 11, 384, 21 ], [ 31, 21, 39, 31 ], [ 41, 21, 84, 31 ], [ 87, 21, 133, ...	Which drug's toxicity study results will be discussed ?	pioglitazone
535	[ "Task", "Notes", "Lead", "Responsibility", "Due", "Date", "4.", "PEDIATRIC", "STUDIES", "(CONTINUED)", "Evaluate", "data", "from", "Actos", "507", ">", "Evaluate", "data", "to", "support", "Amy", "Hagaman", "August", "5", "ustification", "to", "proceed", "with",...	[ [ 174, 101, 207, 115 ], [ 385, 101, 437, 115 ], [ 534, 101, 576, 116 ], [ 580, 101, 705, 117 ], [ 768, 102, 805, 116 ], [ 808, 103, 850, 116 ], [ 90, 122, 104, 135 ], [ 107...	How many pages are there in total as part of this document?	7
540	[ "ACTOS", "FDA", "Response", "Meeting", "August", "12-13,", "2002", "Page", "4", "of", "4", "Highlights", "from", "Cohen", "Hypothesis", "Discussion", ">", "Philip", "Collett", "presented", "an", "outline", "of", "the", "Cohen", "hypothesis", "Male", "rat", "ur...	[ [ 654, 43, 693, 55 ], [ 695, 43, 720, 54 ], [ 722, 43, 777, 54 ], [ 780, 44, 824, 55 ], [ 713, 55, 754, 65 ], [ 757, 55, 795, 65 ], [ 797, 55, 825, 65 ], [ 760, 66, ...	Who challenged authorities regrading implementing monitoring plan?	Takeda Europe
540	[ "ACTOS", "FDA", "Response", "Meeting", "August", "12-13,", "2002", "Page", "4", "of", "4", "Highlights", "from", "Cohen", "Hypothesis", "Discussion", ">", "Philip", "Collett", "presented", "an", "outline", "of", "the", "Cohen", "hypothesis", "Male", "rat", "ur...	[ [ 654, 43, 693, 55 ], [ 695, 43, 720, 54 ], [ 722, 43, 777, 54 ], [ 780, 44, 824, 55 ], [ 713, 55, 754, 65 ], [ 757, 55, 795, 65 ], [ 797, 55, 825, 65 ], [ 760, 66, ...	What content is high in male rat urine?	protein
550	[ "ACTOS", "FDA", "RESPONSE", "MEETING", "TPNA/TEUR&D/TCI", "AUGUST", "12-13,", "2002", "Attendees:", "TPNA", "TEUR&D", "Sam", "Hamanaka", "David", "Eckland", "Claire", "Thom", "Yasuhiko", "Wada", "Ingrid", "Hood", "Glyn", "Belcher", "Alfonso", "Perez", "Philip", "C...	[ [ 197, 92, 332, 122 ], [ 340, 92, 420, 122 ], [ 432, 92, 612, 122 ], [ 620, 93, 776, 122 ], [ 327, 131, 650, 159 ], [ 373, 164, 456, 183 ], [ 460, 164, 534, 184 ], [ 538, ...	What kind of meeting is mentioned in this letter?	ACTOS FDA RESPONSE MEETING
550	[ "ACTOS", "FDA", "RESPONSE", "MEETING", "TPNA/TEUR&D/TCI", "AUGUST", "12-13,", "2002", "Attendees:", "TPNA", "TEUR&D", "Sam", "Hamanaka", "David", "Eckland", "Claire", "Thom", "Yasuhiko", "Wada", "Ingrid", "Hood", "Glyn", "Belcher", "Alfonso", "Perez", "Philip", "C...	[ [ 197, 92, 332, 122 ], [ 340, 92, 420, 122 ], [ 432, 92, 612, 122 ], [ 620, 93, 776, 122 ], [ 327, 131, 650, 159 ], [ 373, 164, 456, 183 ], [ 460, 164, 534, 184 ], [ 538, ...	what kind of drug is used to treat the group of rats?	Pioglitazone
552	[ "ACTOS", "FDA", "Response", "Meeting", "August", "12-13,", "2002", "Page", "3", "of", "4", "Highlights/", "Discussion", "Points", "from", "Preclinical", "Data", "Presentation", "In", "the", "rat", "oncogenicity", "study,", "thickening", "of", "the", "bladder", "...	[ [ 654, 43, 692, 55 ], [ 695, 43, 720, 54 ], [ 723, 43, 777, 54 ], [ 780, 44, 824, 55 ], [ 714, 55, 754, 66 ], [ 757, 54, 795, 65 ], [ 797, 54, 824, 66 ], [ 760, 66, ...	In the rat oncogenicity study, what was observed in male rats?	thickening of the bladder and hypertrophy of the urothelium
551	[ "Task", "Notes", "Lead", "Responsibility", "Due", "Date", "6.", "INTRODUCTORY/CONCLUSION", "STATEMENTS", "(CONTINUED)", "Send", "nonclinical", "David", "Baron", "August", "20", "rationale/justification", "section", "to", "medical", "writing", "for", "compilation", "Comp...	[ [ 175, 100, 211, 113 ], [ 389, 102, 440, 114 ], [ 536, 102, 578, 116 ], [ 582, 102, 706, 117 ], [ 772, 103, 808, 116 ], [ 813, 104, 854, 116 ], [ 91, 123, 106, 135 ], [ 109...	What is the due date to conduct review meeting for FDA package?	August 22
552	[ "ACTOS", "FDA", "Response", "Meeting", "August", "12-13,", "2002", "Page", "3", "of", "4", "Highlights/", "Discussion", "Points", "from", "Preclinical", "Data", "Presentation", "In", "the", "rat", "oncogenicity", "study,", "thickening", "of", "the", "bladder", "...	[ [ 654, 43, 692, 55 ], [ 695, 43, 720, 54 ], [ 723, 43, 777, 54 ], [ 780, 44, 824, 55 ], [ 714, 55, 754, 66 ], [ 757, 54, 795, 65 ], [ 797, 54, 824, 66 ], [ 760, 66, ...	What is the time span where no tumors are seen?	shorter term (12 month)
551	[ "Task", "Notes", "Lead", "Responsibility", "Due", "Date", "6.", "INTRODUCTORY/CONCLUSION", "STATEMENTS", "(CONTINUED)", "Send", "nonclinical", "David", "Baron", "August", "20", "rationale/justification", "section", "to", "medical", "writing", "for", "compilation", "Comp...	[ [ 175, 100, 211, 113 ], [ 389, 102, 440, 114 ], [ 536, 102, 578, 116 ], [ 582, 102, 706, 117 ], [ 772, 103, 808, 116 ], [ 813, 104, 854, 116 ], [ 91, 123, 106, 135 ], [ 109...	Who is the lead responsible person for the compilation of FDA package?	Larry Hancock
552	[ "ACTOS", "FDA", "Response", "Meeting", "August", "12-13,", "2002", "Page", "3", "of", "4", "Highlights/", "Discussion", "Points", "from", "Preclinical", "Data", "Presentation", "In", "the", "rat", "oncogenicity", "study,", "thickening", "of", "the", "bladder", "...	[ [ 654, 43, 692, 55 ], [ 695, 43, 720, 54 ], [ 723, 43, 777, 54 ], [ 780, 44, 824, 55 ], [ 714, 55, 754, 66 ], [ 757, 54, 795, 65 ], [ 797, 54, 824, 66 ], [ 760, 66, ...	According to mouse oncogenicity study, what was seen male mice only?	hyperplasia
550	[ "ACTOS", "FDA", "RESPONSE", "MEETING", "TPNA/TEUR&D/TCI", "AUGUST", "12-13,", "2002", "Attendees:", "TPNA", "TEUR&D", "Sam", "Hamanaka", "David", "Eckland", "Claire", "Thom", "Yasuhiko", "Wada", "Ingrid", "Hood", "Glyn", "Belcher", "Alfonso", "Perez", "Philip", "C...	[ [ 197, 92, 332, 122 ], [ 340, 92, 420, 122 ], [ 432, 92, 612, 122 ], [ 620, 93, 776, 122 ], [ 327, 131, 650, 159 ], [ 373, 164, 456, 183 ], [ 460, 164, 534, 184 ], [ 538, ...	what kind of cell tumours experienced the same frequency when group of rats treated with pioglitazone?	transitional
552	[ "ACTOS", "FDA", "Response", "Meeting", "August", "12-13,", "2002", "Page", "3", "of", "4", "Highlights/", "Discussion", "Points", "from", "Preclinical", "Data", "Presentation", "In", "the", "rat", "oncogenicity", "study,", "thickening", "of", "the", "bladder", "...	[ [ 654, 43, 692, 55 ], [ 695, 43, 720, 54 ], [ 723, 43, 777, 54 ], [ 780, 44, 824, 55 ], [ 714, 55, 754, 66 ], [ 757, 54, 795, 65 ], [ 797, 54, 824, 66 ], [ 760, 66, ...	who conducted robust program?	TCI
551	[ "Task", "Notes", "Lead", "Responsibility", "Due", "Date", "6.", "INTRODUCTORY/CONCLUSION", "STATEMENTS", "(CONTINUED)", "Send", "nonclinical", "David", "Baron", "August", "20", "rationale/justification", "section", "to", "medical", "writing", "for", "compilation", "Comp...	[ [ 175, 100, 211, 113 ], [ 389, 102, 440, 114 ], [ 536, 102, 578, 116 ], [ 582, 102, 706, 117 ], [ 772, 103, 808, 116 ], [ 813, 104, 854, 116 ], [ 91, 123, 106, 135 ], [ 109...	What is the task assigned to David Baron?	Send nonclinical rationale/justification section to medical writing for compilation
551	[ "Task", "Notes", "Lead", "Responsibility", "Due", "Date", "6.", "INTRODUCTORY/CONCLUSION", "STATEMENTS", "(CONTINUED)", "Send", "nonclinical", "David", "Baron", "August", "20", "rationale/justification", "section", "to", "medical", "writing", "for", "compilation", "Comp...	[ [ 175, 100, 211, 113 ], [ 389, 102, 440, 114 ], [ 536, 102, 578, 116 ], [ 582, 102, 706, 117 ], [ 772, 103, 808, 116 ], [ 813, 104, 854, 116 ], [ 91, 123, 106, 135 ], [ 109...	Who is responsible for sending package to TCI/EU for review?	Mary Ramstack
551	[ "Task", "Notes", "Lead", "Responsibility", "Due", "Date", "6.", "INTRODUCTORY/CONCLUSION", "STATEMENTS", "(CONTINUED)", "Send", "nonclinical", "David", "Baron", "August", "20", "rationale/justification", "section", "to", "medical", "writing", "for", "compilation", "Comp...	[ [ 175, 100, 211, 113 ], [ 389, 102, 440, 114 ], [ 536, 102, 578, 116 ], [ 582, 102, 706, 117 ], [ 772, 103, 808, 116 ], [ 813, 104, 854, 116 ], [ 91, 123, 106, 135 ], [ 109...	What is the due date for sending FDA Document to Regulatory Affairs?	August 26
551	[ "Task", "Notes", "Lead", "Responsibility", "Due", "Date", "6.", "INTRODUCTORY/CONCLUSION", "STATEMENTS", "(CONTINUED)", "Send", "nonclinical", "David", "Baron", "August", "20", "rationale/justification", "section", "to", "medical", "writing", "for", "compilation", "Comp...	[ [ 175, 100, 211, 113 ], [ 389, 102, 440, 114 ], [ 536, 102, 578, 116 ], [ 582, 102, 706, 117 ], [ 772, 103, 808, 116 ], [ 813, 104, 854, 116 ], [ 91, 123, 106, 135 ], [ 109...	What is the last updated date mentioned in this document?	August 1, 2002
554	[ "Horizon", "-", "ACTOS", "PRODUCTS", "LIABILITY", "CLAIMS", "Page", "1", "of", "2", "Home", "News", "&", "Events", "People", "Workplace", "&", "Services", "Culture", "&", "Values", "Tools", "&", "Resources", "Team", "Horton", "ACTOS", "PRODUCTS", "LIABILITY", ...	[ [ 125, 39, 187, 54 ], [ 191, 40, 198, 54 ], [ 202, 40, 263, 55 ], [ 267, 40, 366, 55 ], [ 370, 39, 464, 55 ], [ 468, 38, 541, 55 ], [ 824, 40, 862, 55 ], [ 866, 40, ...	Which product's liability claims are described here?	ACTOS PRODUCTS
554	[ "Horizon", "-", "ACTOS", "PRODUCTS", "LIABILITY", "CLAIMS", "Page", "1", "of", "2", "Home", "News", "&", "Events", "People", "Workplace", "&", "Services", "Culture", "&", "Values", "Tools", "&", "Resources", "Team", "Horton", "ACTOS", "PRODUCTS", "LIABILITY", ...	[ [ 125, 39, 187, 54 ], [ 191, 40, 198, 54 ], [ 202, 40, 263, 55 ], [ 267, 40, 366, 55 ], [ 370, 39, 464, 55 ], [ 468, 38, 541, 55 ], [ 824, 40, 862, 55 ], [ 866, 40, ...	What is the date mentioned in this document at the bottom?	1/11/2007
553	[ "PROactive'", "Executive", "Committee", "Conference", "Call", "Minutes", "of", "Conference", "Call", "Date:", "Monday", "28\"", "November", "2005", "EXHIBIT", "NO.", "Time:", "1900", "hours", "In", "attendance:", "Professor", "Erland", "Erdmann", "(EE)", "rmandy", ...	[ [ 220, 103, 413, 125 ], [ 470, 105, 569, 122 ], [ 573, 105, 681, 122 ], [ 686, 104, 800, 122 ], [ 805, 104, 844, 122 ], [ 440, 166, 496, 178 ], [ 498, 167, 513, 178 ], [ 51...	Mention the first name listed in the "apologies"?	Professor Ele Ferrannini
554	[ "Horizon", "-", "ACTOS", "PRODUCTS", "LIABILITY", "CLAIMS", "Page", "1", "of", "2", "Home", "News", "&", "Events", "People", "Workplace", "&", "Services", "Culture", "&", "Values", "Tools", "&", "Resources", "Team", "Horton", "ACTOS", "PRODUCTS", "LIABILITY", ...	[ [ 125, 39, 187, 54 ], [ 191, 40, 198, 54 ], [ 202, 40, 263, 55 ], [ 267, 40, 366, 55 ], [ 370, 39, 464, 55 ], [ 468, 38, 541, 55 ], [ 824, 40, 862, 55 ], [ 866, 40, ...	What is the exhibit number?	52
553	[ "PROactive'", "Executive", "Committee", "Conference", "Call", "Minutes", "of", "Conference", "Call", "Date:", "Monday", "28\"", "November", "2005", "EXHIBIT", "NO.", "Time:", "1900", "hours", "In", "attendance:", "Professor", "Erland", "Erdmann", "(EE)", "rmandy", ...	[ [ 220, 103, 413, 125 ], [ 470, 105, 569, 122 ], [ 573, 105, 681, 122 ], [ 686, 104, 800, 122 ], [ 805, 104, 844, 122 ], [ 440, 166, 496, 178 ], [ 498, 167, 513, 178 ], [ 51...	when was the last meeting/conference call held on ?	15th October 2005
542	[ "107", "FDA", "Conference", "Call:", "August", "13,", "2002", "PENGAD", "800-631-698", "EXHIBIT", "FDA", "Personnel:", "Jeri", "El-Hage,", "Ph.D.,", "Toxicology", "Team", "Leader", "Jena", "Weber,", "Project", "Manager", "TPNA", "Personnel:", "David", "Baron,", "P...	[ [ 785, 93, 849, 115 ], [ 170, 120, 206, 133 ], [ 211, 120, 304, 134 ], [ 307, 120, 350, 135 ], [ 355, 120, 413, 135 ], [ 417, 120, 440, 135 ], [ 442, 119, 481, 135 ], [ 728...	What is the exhibit number?	107
553	[ "PROactive'", "Executive", "Committee", "Conference", "Call", "Minutes", "of", "Conference", "Call", "Date:", "Monday", "28\"", "November", "2005", "EXHIBIT", "NO.", "Time:", "1900", "hours", "In", "attendance:", "Professor", "Erland", "Erdmann", "(EE)", "rmandy", ...	[ [ 220, 103, 413, 125 ], [ 470, 105, 569, 122 ], [ 573, 105, 681, 122 ], [ 686, 104, 800, 122 ], [ 805, 104, 844, 122 ], [ 440, 166, 496, 178 ], [ 498, 167, 513, 178 ], [ 51...	what is the date mentioned under the title - " minutes of conference call"?	Monday 28th November 2005
558	[ "Rationale", "for", "3", "Segments", "actos", "pioglitazone", "HCI", "For", "performance", "that", "benefits", "the", "body.", "Summary", "of", "Segment", "Attractiveness", "(based", "on", "current", "situation", "&", "future", "trends)", "Treatment", "Machines,", ...	[ [ 93, 134, 279, 188 ], [ 290, 134, 349, 190 ], [ 355, 134, 381, 190 ], [ 392, 134, 590, 195 ], [ 784, 104, 941, 151 ], [ 782, 147, 904, 179 ], [ 908, 145, 945, 176 ], [ 783...	What is the heading of this document?	Rationale for 3 segments
556	[ "(2)", "The", "person", "in", "charge", "of", "storage", "shall", "properly", "store,", "and", "dispose", "of,", "any", "stored", "documents", "assigned,", "and", "properly", "store", "any", "records", "relevant", "to", "those", "storage", "and", "disposal.", ...	[ [ 130, 118, 158, 133 ], [ 162, 118, 188, 133 ], [ 191, 118, 240, 134 ], [ 243, 118, 259, 134 ], [ 262, 118, 311, 134 ], [ 314, 118, 328, 134 ], [ 332, 118, 384, 134 ], [ 38...	what is the title of chapter 3?	Document Storage Period
558	[ "Rationale", "for", "3", "Segments", "actos", "pioglitazone", "HCI", "For", "performance", "that", "benefits", "the", "body.", "Summary", "of", "Segment", "Attractiveness", "(based", "on", "current", "situation", "&", "future", "trends)", "Treatment", "Machines,", ...	[ [ 93, 134, 279, 188 ], [ 290, 134, 349, 190 ], [ 355, 134, 381, 190 ], [ 392, 134, 590, 195 ], [ 784, 104, 941, 151 ], [ 782, 147, 904, 179 ], [ 908, 145, 945, 176 ], [ 783...	What is the graphical representation about?	Summary of Segment Attractiveness
558	[ "Rationale", "for", "3", "Segments", "actos", "pioglitazone", "HCI", "For", "performance", "that", "benefits", "the", "body.", "Summary", "of", "Segment", "Attractiveness", "(based", "on", "current", "situation", "&", "future", "trends)", "Treatment", "Machines,", ...	[ [ 93, 134, 279, 188 ], [ 290, 134, 349, 190 ], [ 355, 134, 381, 190 ], [ 392, 134, 590, 195 ], [ 784, 104, 941, 151 ], [ 782, 147, 904, 179 ], [ 908, 145, 945, 176 ], [ 783...	On what basis, the Summary of Segment Attractiveness is carried out?	based on current situation & future trends
558	[ "Rationale", "for", "3", "Segments", "actos", "pioglitazone", "HCI", "For", "performance", "that", "benefits", "the", "body.", "Summary", "of", "Segment", "Attractiveness", "(based", "on", "current", "situation", "&", "future", "trends)", "Treatment", "Machines,", ...	[ [ 93, 134, 279, 188 ], [ 290, 134, 349, 190 ], [ 355, 134, 381, 190 ], [ 392, 134, 590, 195 ], [ 784, 104, 941, 151 ], [ 782, 147, 904, 179 ], [ 908, 145, 945, 176 ], [ 783...	What are the three segments indicated in the graph?	Treatment Machines, Life Negotiators, Struggle for Control
556	[ "(2)", "The", "person", "in", "charge", "of", "storage", "shall", "properly", "store,", "and", "dispose", "of,", "any", "stored", "documents", "assigned,", "and", "properly", "store", "any", "records", "relevant", "to", "those", "storage", "and", "disposal.", ...	[ [ 130, 118, 158, 133 ], [ 162, 118, 188, 133 ], [ 191, 118, 240, 134 ], [ 243, 118, 259, 134 ], [ 262, 118, 311, 134 ], [ 314, 118, 328, 134 ], [ 332, 118, 384, 134 ], [ 38...	what is the "document storage period " article number?	7
558	[ "Rationale", "for", "3", "Segments", "actos", "pioglitazone", "HCI", "For", "performance", "that", "benefits", "the", "body.", "Summary", "of", "Segment", "Attractiveness", "(based", "on", "current", "situation", "&", "future", "trends)", "Treatment", "Machines,", ...	[ [ 93, 134, 279, 188 ], [ 290, 134, 349, 190 ], [ 355, 134, 381, 190 ], [ 392, 134, 590, 195 ], [ 784, 104, 941, 151 ], [ 782, 147, 904, 179 ], [ 908, 145, 945, 176 ], [ 783...	What is the conclusion obtained from the graph?	All 3 segments have consistent needs
556	[ "(2)", "The", "person", "in", "charge", "of", "storage", "shall", "properly", "store,", "and", "dispose", "of,", "any", "stored", "documents", "assigned,", "and", "properly", "store", "any", "records", "relevant", "to", "those", "storage", "and", "disposal.", ...	[ [ 130, 118, 158, 133 ], [ 162, 118, 188, 133 ], [ 191, 118, 240, 134 ], [ 243, 118, 259, 134 ], [ 262, 118, 311, 134 ], [ 314, 118, 328, 134 ], [ 332, 118, 384, 134 ], [ 38...	mention the second point listed under the article 7(document storage period)?	To be stored for ten years
557	[ "3)", "Other", "places", "designated", "by", "the", "relevant", "core", "organizations", ".", "\"Responsible", "person", "in", "charge", "of", "storage\"", "shall", "mean", "the", "responsible", "person", "in", "charge", "of", "a", "core", "organization.", "5.",...	[ [ 188, 118, 212, 134 ], [ 223, 118, 264, 134 ], [ 267, 118, 317, 135 ], [ 320, 119, 392, 135 ], [ 396, 119, 415, 135 ], [ 418, 119, 441, 135 ], [ 445, 119, 503, 135 ], [ 50...	what is article 4?	(PRINCIPLES OF CREATING DOCUMENTS)
580	[ "Summary", "of", "Terms", "for", "OUS", "Agreement", "License", "Exclusive", "rights", "in", "approximately", "60", "countries", "Semi", "exclusive", "rights", "in", "approximately", "20", "countries", "Upfront", "Fee", "$20", "million", "signing", "fee", "with", ...	[ [ 251, 182, 338, 198 ], [ 342, 182, 362, 197 ], [ 366, 182, 420, 197 ], [ 424, 182, 450, 197 ], [ 453, 182, 495, 197 ], [ 499, 182, 595, 199 ], [ 281, 201, 337, 214 ], [ 28...	Semi exclusive rights in how many countries?	20
557	[ "3)", "Other", "places", "designated", "by", "the", "relevant", "core", "organizations", ".", "\"Responsible", "person", "in", "charge", "of", "storage\"", "shall", "mean", "the", "responsible", "person", "in", "charge", "of", "a", "core", "organization.", "5.",...	[ [ 188, 118, 212, 134 ], [ 223, 118, 264, 134 ], [ 267, 118, 317, 135 ], [ 320, 119, 392, 135 ], [ 396, 119, 415, 135 ], [ 418, 119, 441, 135 ], [ 445, 119, 503, 135 ], [ 50...	what is the title of chapter 2?	DOCUMENT STORAGE FUNCTIONS
580	[ "Summary", "of", "Terms", "for", "OUS", "Agreement", "License", "Exclusive", "rights", "in", "approximately", "60", "countries", "Semi", "exclusive", "rights", "in", "approximately", "20", "countries", "Upfront", "Fee", "$20", "million", "signing", "fee", "with", ...	[ [ 251, 182, 338, 198 ], [ 342, 182, 362, 197 ], [ 366, 182, 420, 197 ], [ 424, 182, 450, 197 ], [ 453, 182, 495, 197 ], [ 499, 182, 595, 199 ], [ 281, 201, 337, 214 ], [ 28...	What percent is the Supply Price / Royalty Rate?	30% SUPPLY PRICE
557	[ "3)", "Other", "places", "designated", "by", "the", "relevant", "core", "organizations", ".", "\"Responsible", "person", "in", "charge", "of", "storage\"", "shall", "mean", "the", "responsible", "person", "in", "charge", "of", "a", "core", "organization.", "5.",...	[ [ 188, 118, 212, 134 ], [ 223, 118, 264, 134 ], [ 267, 118, 317, 135 ], [ 320, 119, 392, 135 ], [ 396, 119, 415, 135 ], [ 418, 119, 441, 135 ], [ 445, 119, 503, 135 ], [ 50...	What does article 5 in this document describes?	(principles concerning document storage functions)
557	[ "3)", "Other", "places", "designated", "by", "the", "relevant", "core", "organizations", ".", "\"Responsible", "person", "in", "charge", "of", "storage\"", "shall", "mean", "the", "responsible", "person", "in", "charge", "of", "a", "core", "organization.", "5.",...	[ [ 188, 118, 212, 134 ], [ 223, 118, 264, 134 ], [ 267, 118, 317, 135 ], [ 320, 119, 392, 135 ], [ 396, 119, 415, 135 ], [ 418, 119, 441, 135 ], [ 445, 119, 503, 135 ], [ 50...	what is article 6?	DUTIES OF RESPONSIBLE PERSON IN CHARGE OF STORAGE AND PERSON IN CHARGE OF STORAGE
580	[ "Summary", "of", "Terms", "for", "OUS", "Agreement", "License", "Exclusive", "rights", "in", "approximately", "60", "countries", "Semi", "exclusive", "rights", "in", "approximately", "20", "countries", "Upfront", "Fee", "$20", "million", "signing", "fee", "with", ...	[ [ 251, 182, 338, 198 ], [ 342, 182, 362, 197 ], [ 366, 182, 420, 197 ], [ 424, 182, 450, 197 ], [ 453, 182, 495, 197 ], [ 499, 182, 595, 199 ], [ 281, 201, 337, 214 ], [ 28...	In how many countires, license to Exclusive rights are provided?	in approximately 60 countries
560	[ "ACTOS", "Pediatric", "Program", "5", "October", "2006", "TAK-TROOSA-00427563", "Source:", "https://www.industrydocu?<", "<-09001", "cuments.ucsf.edu/docs/jfkf0226" ]	[ [ 202, 298, 369, 357 ], [ 388, 298, 588, 362 ], [ 599, 301, 777, 367 ], [ 202, 514, 225, 560 ], [ 235, 514, 388, 560 ], [ 394, 515, 483, 560 ], [ 13, 805, 27, 982 ], [ 290,...	what is the name of pediatric program?	ACTOS
560	[ "ACTOS", "Pediatric", "Program", "5", "October", "2006", "TAK-TROOSA-00427563", "Source:", "https://www.industrydocu?<", "<-09001", "cuments.ucsf.edu/docs/jfkf0226" ]	[ [ 202, 298, 369, 357 ], [ 388, 298, 588, 362 ], [ 599, 301, 777, 367 ], [ 202, 514, 225, 560 ], [ 235, 514, 388, 560 ], [ 394, 515, 483, 560 ], [ 13, 805, 27, 982 ], [ 290,...	What is the date mentioned in this page?	5 October 2006
573	[ "Alex", "OD", "PoRET", "Critical", "Success", "Factors", "actos", "pioglitazone", "HCI", "For", "performance", "that", "benefits", "the", "body", "1.", "Condition", "the", "Market", "on", "IR", "and", "its", "link", "to", "CV", "risk", "including", "lipid", ...	[ [ 808, 77, 843, 95 ], [ 845, 78, 861, 95 ], [ 863, 78, 897, 95 ], [ 81, 131, 250, 191 ], [ 259, 131, 441, 191 ], [ 450, 133, 610, 190 ], [ 806, 93, 938, 140 ], [ 808, 1...	What is the title of this document?	CRITICAL SUCCESS FACTORS
570	[ "Consequences", "of", "IR", "Damage", "to", "Eyes", "Damage", "to", "Kidneys", "HDL-C", "LDL-C", "Damage", "to", "Nerves", "Increased", "CV", "Risk", "Increased", "CV", "Risk", "Hyperglycemia", "Dyslipidemia", "Insulin", "Resistance", "Central", "Obesity", "Hypert...	[ [ 94, 115, 391, 164 ], [ 400, 115, 443, 163 ], [ 450, 114, 490, 161 ], [ 175, 239, 247, 262 ], [ 251, 240, 269, 263 ], [ 274, 240, 316, 263 ], [ 160, 275, 234, 297 ], [ 236...	What is the title of this document?	Consequences of IR
586	[ "TZD", "Share", "of", "Oral", "Market", "%", "Retail", "TRx", "Share", "25%", "Actual", "Forecast", "20%", "15%", "10%", "5%", "0%", "Apr-01", "Jul-01", "Oct-01", "Jan-02", "Apr-02", "1-02", "-03", "Oct-", "Jan", "Apr-03", "Jul-03", "Jan-04", "Apr-04", "Ju...	[ [ 96, 107, 158, 148 ], [ 176, 106, 277, 151 ], [ 288, 106, 329, 151 ], [ 335, 106, 411, 151 ], [ 416, 107, 538, 151 ], [ 96, 195, 108, 219 ], [ 113, 195, 164, 220 ], [ 168,...	What does the graph describes in this document?	TZD SHARE OF ORAL MARKET
586	[ "TZD", "Share", "of", "Oral", "Market", "%", "Retail", "TRx", "Share", "25%", "Actual", "Forecast", "20%", "15%", "10%", "5%", "0%", "Apr-01", "Jul-01", "Oct-01", "Jan-02", "Apr-02", "1-02", "-03", "Oct-", "Jan", "Apr-03", "Jul-03", "Jan-04", "Apr-04", "Ju...	[ [ 96, 107, 158, 148 ], [ 176, 106, 277, 151 ], [ 288, 106, 329, 151 ], [ 335, 106, 411, 151 ], [ 416, 107, 538, 151 ], [ 96, 195, 108, 219 ], [ 113, 195, 164, 220 ], [ 168,...	What is the Plan TZD Share for the year 2003?	19.7%
586	[ "TZD", "Share", "of", "Oral", "Market", "%", "Retail", "TRx", "Share", "25%", "Actual", "Forecast", "20%", "15%", "10%", "5%", "0%", "Apr-01", "Jul-01", "Oct-01", "Jan-02", "Apr-02", "1-02", "-03", "Oct-", "Jan", "Apr-03", "Jul-03", "Jan-04", "Apr-04", "Ju...	[ [ 96, 107, 158, 148 ], [ 176, 106, 277, 151 ], [ 288, 106, 329, 151 ], [ 335, 106, 411, 151 ], [ 416, 107, 538, 151 ], [ 96, 195, 108, 219 ], [ 113, 195, 164, 220 ], [ 168,...	Which year has 13.3% Oral share (TZD)?	2000
571	[ "Clinical", "Study", "Synopsis", "01-06-TL-OPI-527", "o", "Expert", "advisory", "meeting", "4", "October", "2006", "o", "Draft", "synopsis", "available", "for", "team", "review", "on", "Monday,", "9", "October", "2006", "o", "Team", "proposing", "to", "review", ...	[ [ 191, 122, 330, 176 ], [ 336, 122, 439, 180 ], [ 450, 122, 609, 180 ], [ 191, 186, 519, 233 ], [ 188, 313, 207, 351 ], [ 224, 312, 332, 354 ], [ 337, 312, 472, 355 ], [ 48...	Which study's synopsis is this?	Clinical Study
571	[ "Clinical", "Study", "Synopsis", "01-06-TL-OPI-527", "o", "Expert", "advisory", "meeting", "4", "October", "2006", "o", "Draft", "synopsis", "available", "for", "team", "review", "on", "Monday,", "9", "October", "2006", "o", "Team", "proposing", "to", "review", ...	[ [ 191, 122, 330, 176 ], [ 336, 122, 439, 180 ], [ 450, 122, 609, 180 ], [ 191, 186, 519, 233 ], [ 188, 313, 207, 351 ], [ 224, 312, 332, 354 ], [ 337, 312, 472, 355 ], [ 48...	what is the code mentioned under the title of clinical study synopsis?	01-06-TL-OPI-527
571	[ "Clinical", "Study", "Synopsis", "01-06-TL-OPI-527", "o", "Expert", "advisory", "meeting", "4", "October", "2006", "o", "Draft", "synopsis", "available", "for", "team", "review", "on", "Monday,", "9", "October", "2006", "o", "Team", "proposing", "to", "review", ...	[ [ 191, 122, 330, 176 ], [ 336, 122, 439, 180 ], [ 450, 122, 609, 180 ], [ 191, 186, 519, 233 ], [ 188, 313, 207, 351 ], [ 224, 312, 332, 354 ], [ 337, 312, 472, 355 ], [ 48...	When was expert advisory meeting ?	4 OCTOBER 2006
599	[ "Overview", "of", "November", "2006", "Submission", "o", "PPSR", "(Proposed", "Pediatric", "Study", "Request)", "NEED", "TO", "CONFIRM", "FORMAT", "Clinical", "study", "synopsis", "TAK-TROOSA-00427563", "Source:", "https://www.industrydocuments.ucsf.edu/docs/jfkf0226" ]	[ [ 191, 121, 356, 171 ], [ 370, 121, 409, 171 ], [ 416, 122, 610, 171 ], [ 617, 122, 702, 170 ], [ 192, 185, 398, 233 ], [ 191, 310, 214, 353 ], [ 226, 309, 317, 355 ], [ 33...	What is the title of this document?	OVERVIEW OF NOVEMBER 2006 SUBMISSION
599	[ "Overview", "of", "November", "2006", "Submission", "o", "PPSR", "(Proposed", "Pediatric", "Study", "Request)", "NEED", "TO", "CONFIRM", "FORMAT", "Clinical", "study", "synopsis", "TAK-TROOSA-00427563", "Source:", "https://www.industrydocuments.ucsf.edu/docs/jfkf0226" ]	[ [ 191, 121, 356, 171 ], [ 370, 121, 409, 171 ], [ 416, 122, 610, 171 ], [ 617, 122, 702, 170 ], [ 192, 185, 398, 233 ], [ 191, 310, 214, 353 ], [ 226, 309, 317, 355 ], [ 33...	What is the full form of PPSR?	PROPOSED PEDIATRIC STUDY REQUEST
605	[ "NDA", "21-073/S-023", "Page", "9", "Table", "2", "shows", "HbAy,", "and", "FPG", "values", "for", "the", "entire", "study", "population.", "Table", "2", "Glycemic", "Parameters", "in", "a", "26-Week", "Placebo-Controlled", "Dose-Ranging", "Study", "Placeb", "AC...	[ [ 112, 62, 154, 77 ], [ 158, 62, 258, 77 ], [ 114, 78, 152, 92 ], [ 155, 78, 164, 91 ], [ 118, 108, 158, 120 ], [ 160, 108, 171, 120 ], [ 172, 108, 216, 120 ], [ 219, 1...	What study is described in the table given?	Glycemic Parameters in a 26-Week Placebo-Controlled Dose-Ranging Study.
605	[ "NDA", "21-073/S-023", "Page", "9", "Table", "2", "shows", "HbAy,", "and", "FPG", "values", "for", "the", "entire", "study", "population.", "Table", "2", "Glycemic", "Parameters", "in", "a", "26-Week", "Placebo-Controlled", "Dose-Ranging", "Study", "Placeb", "AC...	[ [ 112, 62, 154, 77 ], [ 158, 62, 258, 77 ], [ 114, 78, 152, 92 ], [ 155, 78, 164, 91 ], [ 118, 108, 158, 120 ], [ 160, 108, 171, 120 ], [ 172, 108, 216, 120 ], [ 219, 1...	Which parameters are considered for the study(see heading of table 2)?	Glycemic Parameters
605	[ "NDA", "21-073/S-023", "Page", "9", "Table", "2", "shows", "HbAy,", "and", "FPG", "values", "for", "the", "entire", "study", "population.", "Table", "2", "Glycemic", "Parameters", "in", "a", "26-Week", "Placebo-Controlled", "Dose-Ranging", "Study", "Placeb", "AC...	[ [ 112, 62, 154, 77 ], [ 158, 62, 258, 77 ], [ 114, 78, 152, 92 ], [ 155, 78, 164, 91 ], [ 118, 108, 158, 120 ], [ 160, 108, 171, 120 ], [ 172, 108, 216, 120 ], [ 219, 1...	Prior to what, the patients entered an 8 week washout/run-in-period?	double-blind treatment
579	[ "Overview", "of", "Major", "Contract", "Terms", "Promotional", "Samples", "At", "Cost", "New", "Indications/Line", "Extension", "Takeda", "must", "offer", "to", "Lilly", "If", "Lilly", "agrees,", "then", "cost", "sharing", "based", "on", "expected", "benefit\"", ...	[ [ 253, 183, 334, 198 ], [ 341, 184, 361, 199 ], [ 364, 184, 415, 199 ], [ 418, 183, 497, 199 ], [ 501, 183, 557, 199 ], [ 237, 207, 331, 221 ], [ 334, 209, 398, 222 ], [ 29...	What is the floor supply price?	$0.17 / 30 mg or Takeda's cost from site of lowest cost
579	[ "Overview", "of", "Major", "Contract", "Terms", "Promotional", "Samples", "At", "Cost", "New", "Indications/Line", "Extension", "Takeda", "must", "offer", "to", "Lilly", "If", "Lilly", "agrees,", "then", "cost", "sharing", "based", "on", "expected", "benefit\"", ...	[ [ 253, 183, 334, 198 ], [ 341, 184, 361, 199 ], [ 364, 184, 415, 199 ], [ 418, 183, 497, 199 ], [ 501, 183, 557, 199 ], [ 237, 207, 331, 221 ], [ 334, 209, 398, 222 ], [ 29...	What is the royalty adjustment if generic enters the market ?	50%
579	[ "Overview", "of", "Major", "Contract", "Terms", "Promotional", "Samples", "At", "Cost", "New", "Indications/Line", "Extension", "Takeda", "must", "offer", "to", "Lilly", "If", "Lilly", "agrees,", "then", "cost", "sharing", "based", "on", "expected", "benefit\"", ...	[ [ 253, 183, 334, 198 ], [ 341, 184, 361, 199 ], [ 364, 184, 415, 199 ], [ 418, 183, 497, 199 ], [ 501, 183, 557, 199 ], [ 237, 207, 331, 221 ], [ 334, 209, 398, 222 ], [ 29...	what is the promotional trails data usage for( Lilly in exclusive) ?	Split of 70/30 (Lilly in Exclusive)
582	[ "CSF's", "and", "Marketing", "Thegys", "Q0", "Power", "actos", "Objectives*", "pioglitazone", "HCI", "For", "performance", "that", "benefits", "the", "body.", "CSF", "#1-", "Condition", "the", "market", "on", "IR", "and", "its", "link", "to", "CV", "risk", "...	[ [ 68, 77, 198, 133 ], [ 205, 77, 290, 135 ], [ 298, 77, 528, 143 ], [ 823, 77, 852, 93 ], [ 854, 77, 869, 93 ], [ 871, 77, 903, 93 ], [ 822, 94, 939, 131 ], [ 63, 151, ...	What is the title mentioned in this document?	CSF'S AND MARKETING OBJECTIVES
579	[ "Overview", "of", "Major", "Contract", "Terms", "Promotional", "Samples", "At", "Cost", "New", "Indications/Line", "Extension", "Takeda", "must", "offer", "to", "Lilly", "If", "Lilly", "agrees,", "then", "cost", "sharing", "based", "on", "expected", "benefit\"", ...	[ [ 253, 183, 334, 198 ], [ 341, 184, 361, 199 ], [ 364, 184, 415, 199 ], [ 418, 183, 497, 199 ], [ 501, 183, 557, 199 ], [ 237, 207, 331, 221 ], [ 334, 209, 398, 222 ], [ 29...	What is the promotional trials data usage for (semi exclusive)?	50/50 in Semi-exclusive
583	[ "Actos", "2004", "Marketing", "Plan", "Review", "DALY", "12", "Lilly", "Answers", "That", "Matter.", "Confidential", "-", "Subject", "to", "Protective", "Order", "LLY-HOVENR-00001895", "Produced", "in", "MDL", "on", "02/27/13", "Source:", "https://www.induposescooouts...	[ [ 270, 315, 383, 363 ], [ 397, 314, 484, 363 ], [ 266, 374, 466, 429 ], [ 473, 375, 562, 429 ], [ 575, 375, 710, 428 ], [ 717, 534, 796, 596 ], [ 802, 531, 840, 589 ], [ 73...	what is the name of the plan review ?	MARKETING PLAN REVIEW
620	[ "ACTOS", "FDA", "Response", "Strategy", "TASK", "FORCE", "-TPNA", "Alfonso", "Perez", "Janet", "Haskins", "Mary", "Ramstack", "Ingrid", "Hoos", "Michael", "Elisseou", "John", "Page", "(Rich", "Wilson)", "Claire", "Thom", "Dan", "Orlando", "David", "Baron", "(C...	[ [ 282, 81, 385, 103 ], [ 394, 81, 451, 104 ], [ 460, 82, 585, 105 ], [ 590, 82, 700, 105 ], [ 162, 133, 211, 148 ], [ 217, 134, 281, 148 ], [ 284, 132, 340, 148 ], [ 163, ...	What is the heading of this document?	ACTOS FDA RESPONSE STRATEGY
620	[ "ACTOS", "FDA", "Response", "Strategy", "TASK", "FORCE", "-TPNA", "Alfonso", "Perez", "Janet", "Haskins", "Mary", "Ramstack", "Ingrid", "Hoos", "Michael", "Elisseou", "John", "Page", "(Rich", "Wilson)", "Claire", "Thom", "Dan", "Orlando", "David", "Baron", "(C...	[ [ 282, 81, 385, 103 ], [ 394, 81, 451, 104 ], [ 460, 82, 585, 105 ], [ 590, 82, 700, 105 ], [ 162, 133, 211, 148 ], [ 217, 134, 281, 148 ], [ 284, 132, 340, 148 ], [ 163, ...	What is the last revision date mentioned in this document?	August 7, 2002
620	[ "ACTOS", "FDA", "Response", "Strategy", "TASK", "FORCE", "-TPNA", "Alfonso", "Perez", "Janet", "Haskins", "Mary", "Ramstack", "Ingrid", "Hoos", "Michael", "Elisseou", "John", "Page", "(Rich", "Wilson)", "Claire", "Thom", "Dan", "Orlando", "David", "Baron", "(C...	[ [ 282, 81, 385, 103 ], [ 394, 81, 451, 104 ], [ 460, 82, 585, 105 ], [ 590, 82, 700, 105 ], [ 162, 133, 211, 148 ], [ 217, 134, 281, 148 ], [ 284, 132, 340, 148 ], [ 163, ...	What is the goal of TPNA?	to supply justification to support maintaining current labeling.
575	[ "Most", "Significant", "Adverse", "Events", "Risks", "for", "Pioglitazone", "Risk", "Onset", "Reversibility", "Clinical", "Findings", "Occurrence", "of", "ALT", "Elevation", "Within", "2", "months", "Only", "through", "Drug", "Placebo", "Liver", "Failure", "Transpla...	[ [ 246, 181, 293, 198 ], [ 297, 181, 392, 198 ], [ 396, 182, 469, 199 ], [ 473, 182, 534, 199 ], [ 538, 182, 588, 199 ], [ 593, 182, 618, 199 ], [ 622, 182, 735, 199 ], [ 25...	what is the first point given in table for bladder cancer alongside of clinical findings ?	OBSERVED DURING PRECLINICAL STUDIES IN RATS
583	[ "Actos", "2004", "Marketing", "Plan", "Review", "DALY", "12", "Lilly", "Answers", "That", "Matter.", "Confidential", "-", "Subject", "to", "Protective", "Order", "LLY-HOVENR-00001895", "Produced", "in", "MDL", "on", "02/27/13", "Source:", "https://www.induposescooouts...	[ [ 270, 315, 383, 363 ], [ 397, 314, 484, 363 ], [ 266, 374, 466, 429 ], [ 473, 375, 562, 429 ], [ 575, 375, 710, 428 ], [ 717, 534, 796, 596 ], [ 802, 531, 840, 589 ], [ 73...	Mention the year given for Actos?	2004
584	[ "Actos", "Share", "of", "TZDs", "Retail", "TRX", "SOM,", "IMS", "Health", "60.00%", "Actual", "Forecast", "50.00%", "40.00%", "Launch", "of", "Launch", "of", "30.00%", "Merck's", "BMS'", "PPAR's", "PPAR's", "Q3", "2005", "20.00%", "Feb", "2005", "10.00%", "0...	[ [ 108, 90, 221, 137 ], [ 234, 89, 351, 138 ], [ 362, 89, 411, 138 ], [ 417, 89, 516, 138 ], [ 106, 197, 156, 220 ], [ 160, 196, 195, 220 ], [ 198, 196, 247, 220 ], [ 250, ...	what is the percentage of TZD share in the year 2000 ?	40.3%
584	[ "Actos", "Share", "of", "TZDs", "Retail", "TRX", "SOM,", "IMS", "Health", "60.00%", "Actual", "Forecast", "50.00%", "40.00%", "Launch", "of", "Launch", "of", "30.00%", "Merck's", "BMS'", "PPAR's", "PPAR's", "Q3", "2005", "20.00%", "Feb", "2005", "10.00%", "0...	[ [ 108, 90, 221, 137 ], [ 234, 89, 351, 138 ], [ 362, 89, 411, 138 ], [ 417, 89, 516, 138 ], [ 106, 197, 156, 220 ], [ 160, 196, 195, 220 ], [ 198, 196, 247, 220 ], [ 250, ...	what is Actos TRx (000s) in the year 2003 ?	9,497
575	[ "Most", "Significant", "Adverse", "Events", "Risks", "for", "Pioglitazone", "Risk", "Onset", "Reversibility", "Clinical", "Findings", "Occurrence", "of", "ALT", "Elevation", "Within", "2", "months", "Only", "through", "Drug", "Placebo", "Liver", "Failure", "Transpla...	[ [ 246, 181, 293, 198 ], [ 297, 181, 392, 198 ], [ 396, 182, 469, 199 ], [ 473, 182, 534, 199 ], [ 538, 182, 588, 199 ], [ 593, 182, 618, 199 ], [ 622, 182, 735, 199 ], [ 25...	how much percent of drug quantity present in rezulin under the title of 'clinical findings'?	1.7%
584	[ "Actos", "Share", "of", "TZDs", "Retail", "TRX", "SOM,", "IMS", "Health", "60.00%", "Actual", "Forecast", "50.00%", "40.00%", "Launch", "of", "Launch", "of", "30.00%", "Merck's", "BMS'", "PPAR's", "PPAR's", "Q3", "2005", "20.00%", "Feb", "2005", "10.00%", "0...	[ [ 108, 90, 221, 137 ], [ 234, 89, 351, 138 ], [ 362, 89, 411, 138 ], [ 417, 89, 516, 138 ], [ 106, 197, 156, 220 ], [ 160, 196, 195, 220 ], [ 198, 196, 247, 220 ], [ 250, ...	what is the percentage of plan TZD share in the year 2004 ?	42.9%
575	[ "Most", "Significant", "Adverse", "Events", "Risks", "for", "Pioglitazone", "Risk", "Onset", "Reversibility", "Clinical", "Findings", "Occurrence", "of", "ALT", "Elevation", "Within", "2", "months", "Only", "through", "Drug", "Placebo", "Liver", "Failure", "Transpla...	[ [ 246, 181, 293, 198 ], [ 297, 181, 392, 198 ], [ 396, 182, 469, 199 ], [ 473, 182, 534, 199 ], [ 538, 182, 588, 199 ], [ 593, 182, 618, 199 ], [ 622, 182, 735, 199 ], [ 25...	how much percent of placebo present in avandia alongside of the clinical findings?	0.20%
584	[ "Actos", "Share", "of", "TZDs", "Retail", "TRX", "SOM,", "IMS", "Health", "60.00%", "Actual", "Forecast", "50.00%", "40.00%", "Launch", "of", "Launch", "of", "30.00%", "Merck's", "BMS'", "PPAR's", "PPAR's", "Q3", "2005", "20.00%", "Feb", "2005", "10.00%", "0...	[ [ 108, 90, 221, 137 ], [ 234, 89, 351, 138 ], [ 362, 89, 411, 138 ], [ 417, 89, 516, 138 ], [ 106, 197, 156, 220 ], [ 160, 196, 195, 220 ], [ 198, 196, 247, 220 ], [ 250, ...	in which month and the year the launch of Merck's PPAR's took place?	FEB 2005
584	[ "Actos", "Share", "of", "TZDs", "Retail", "TRX", "SOM,", "IMS", "Health", "60.00%", "Actual", "Forecast", "50.00%", "40.00%", "Launch", "of", "Launch", "of", "30.00%", "Merck's", "BMS'", "PPAR's", "PPAR's", "Q3", "2005", "20.00%", "Feb", "2005", "10.00%", "0...	[ [ 108, 90, 221, 137 ], [ 234, 89, 351, 138 ], [ 362, 89, 411, 138 ], [ 417, 89, 516, 138 ], [ 106, 197, 156, 220 ], [ 160, 196, 195, 220 ], [ 198, 196, 247, 220 ], [ 250, ...	what is the TZD's TRx (000s) in the year 2005 ?	22,902
575	[ "Most", "Significant", "Adverse", "Events", "Risks", "for", "Pioglitazone", "Risk", "Onset", "Reversibility", "Clinical", "Findings", "Occurrence", "of", "ALT", "Elevation", "Within", "2", "months", "Only", "through", "Drug", "Placebo", "Liver", "Failure", "Transpla...	[ [ 246, 181, 293, 198 ], [ 297, 181, 392, 198 ], [ 396, 182, 469, 199 ], [ 473, 182, 534, 199 ], [ 538, 182, 588, 199 ], [ 593, 182, 618, 199 ], [ 622, 182, 735, 199 ], [ 25...	what is the total number of all claims under the title of "summary of litigation risk in the ous territories"?	10
585	[ "Strategic", "Intent", "&", "CSFs", "Strategic", "Intent:", "Establish", "Actos", "as", "the", "best", "OAD", "medication", "by", "treating", "insulin", "resistance,", "through", "sustained", "glycemic", "control", "and", "reduced", "cardiovascular", "risk.", "Criti...	[ [ 95, 114, 262, 168 ], [ 270, 113, 386, 168 ], [ 393, 113, 419, 165 ], [ 429, 113, 527, 163 ], [ 86, 224, 205, 261 ], [ 210, 224, 297, 261 ], [ 102, 306, 217, 341 ], [ 222,...	what is the first TZD used for type 2 patients ?	ACTOS
585	[ "Strategic", "Intent", "&", "CSFs", "Strategic", "Intent:", "Establish", "Actos", "as", "the", "best", "OAD", "medication", "by", "treating", "insulin", "resistance,", "through", "sustained", "glycemic", "control", "and", "reduced", "cardiovascular", "risk.", "Criti...	[ [ 95, 114, 262, 168 ], [ 270, 113, 386, 168 ], [ 393, 113, 419, 165 ], [ 429, 113, 527, 163 ], [ 86, 224, 205, 261 ], [ 210, 224, 297, 261 ], [ 102, 306, 217, 341 ], [ 222,...	For which type of diabetes the TZD's prescribed earlier in treatment?	Type 2 diabetes
585	[ "Strategic", "Intent", "&", "CSFs", "Strategic", "Intent:", "Establish", "Actos", "as", "the", "best", "OAD", "medication", "by", "treating", "insulin", "resistance,", "through", "sustained", "glycemic", "control", "and", "reduced", "cardiovascular", "risk.", "Criti...	[ [ 95, 114, 262, 168 ], [ 270, 113, 386, 168 ], [ 393, 113, 419, 165 ], [ 429, 113, 527, 163 ], [ 86, 224, 205, 261 ], [ 210, 224, 297, 261 ], [ 102, 306, 217, 341 ], [ 222,...	what has to be establish as the the best OAD medication by treating insulin resistance ?	ACTOS

539

[ "Actos", "Pediatric", "Working", "Group", "Date:", "20", "April", "2006", "Time:", "4:00pm", "-", "5:00pm", "Meeting", "Minutes", "Place:", "Meeting", "Room", "403", "Attendees", "Attendees", "Alfonso", "Perez", "-", "Clinical", "Karen", "Kaluzny", "-", "Project...

[ [ 57, 76, 111, 92 ], [ 114, 77, 197, 92 ], [ 200, 76, 279, 93 ], [ 282, 76, 341, 93 ], [ 410, 76, 460, 91 ], [ 462, 77, 487, 91 ], [ 489, 77, 537, 91 ], [ 539, 76, ...

what is the place mentioned ?

Meeting Room 403

543

[ "Ms.", "Wakamatsu,", "Assistant", "manager,", "Dept.", "Strategic", "Development,", "et", "al.", "Attachment:", "NDA", "schedule", "for", "each", "project", "approved", "on", "the", "5th", "GDC", "1.", "Openings", "Remarks", "Dr.", "Kitazawa", "made", "opening", ...

[ [ 107, 142, 132, 152 ], [ 134, 142, 218, 152 ], [ 220, 142, 280, 153 ], [ 282, 142, 346, 153 ], [ 348, 142, 385, 153 ], [ 387, 142, 446, 153 ], [ 448, 141, 540, 153 ], [ 54...

Why was it suggested to prepare non-clinical "White paper"?

to address the bladder issue

539

[ "Actos", "Pediatric", "Working", "Group", "Date:", "20", "April", "2006", "Time:", "4:00pm", "-", "5:00pm", "Meeting", "Minutes", "Place:", "Meeting", "Room", "403", "Attendees", "Attendees", "Alfonso", "Perez", "-", "Clinical", "Karen", "Kaluzny", "-", "Project...

[ [ 57, 76, 111, 92 ], [ 114, 77, 197, 92 ], [ 200, 76, 279, 93 ], [ 282, 76, 341, 93 ], [ 410, 76, 460, 91 ], [ 462, 77, 487, 91 ], [ 489, 77, 537, 91 ], [ 539, 76, ...

who will forward the article regarding rosiglitazone and non clinical bladder data to andy ?

Mondira

539

[ "Actos", "Pediatric", "Working", "Group", "Date:", "20", "April", "2006", "Time:", "4:00pm", "-", "5:00pm", "Meeting", "Minutes", "Place:", "Meeting", "Room", "403", "Attendees", "Attendees", "Alfonso", "Perez", "-", "Clinical", "Karen", "Kaluzny", "-", "Project...

[ [ 57, 76, 111, 92 ], [ 114, 77, 197, 92 ], [ 200, 76, 279, 93 ], [ 282, 76, 341, 93 ], [ 410, 76, 460, 91 ], [ 462, 77, 487, 91 ], [ 489, 77, 537, 91 ], [ 539, 76, ...

What date is the meeting scheduled to develop the overall structure of the document?

in early May

540

[ "ACTOS", "FDA", "Response", "Meeting", "August", "12-13,", "2002", "Page", "4", "of", "4", "Highlights", "from", "Cohen", "Hypothesis", "Discussion", ">", "Philip", "Collett", "presented", "an", "outline", "of", "the", "Cohen", "hypothesis", "Male", "rat", "ur...

[ [ 654, 43, 693, 55 ], [ 695, 43, 720, 54 ], [ 722, 43, 777, 54 ], [ 780, 44, 824, 55 ], [ 713, 55, 754, 65 ], [ 757, 55, 795, 65 ], [ 797, 55, 825, 65 ], [ 760, 66, ...

Who presented an outline of the Cohen hypothesis?

Philip Collett

540

[ "ACTOS", "FDA", "Response", "Meeting", "August", "12-13,", "2002", "Page", "4", "of", "4", "Highlights", "from", "Cohen", "Hypothesis", "Discussion", ">", "Philip", "Collett", "presented", "an", "outline", "of", "the", "Cohen", "hypothesis", "Male", "rat", "ur...

[ [ 654, 43, 693, 55 ], [ 695, 43, 720, 54 ], [ 722, 43, 777, 54 ], [ 780, 44, 824, 55 ], [ 713, 55, 754, 65 ], [ 757, 55, 795, 65 ], [ 797, 55, 825, 65 ], [ 760, 66, ...

What is significant in the development of calculi?

Raising the pH of male rat urine above 6.5

540

[ "ACTOS", "FDA", "Response", "Meeting", "August", "12-13,", "2002", "Page", "4", "of", "4", "Highlights", "from", "Cohen", "Hypothesis", "Discussion", ">", "Philip", "Collett", "presented", "an", "outline", "of", "the", "Cohen", "hypothesis", "Male", "rat", "ur...

[ [ 654, 43, 693, 55 ], [ 695, 43, 720, 54 ], [ 722, 43, 777, 54 ], [ 780, 44, 824, 55 ], [ 713, 55, 754, 65 ], [ 757, 55, 795, 65 ], [ 797, 55, 825, 65 ], [ 760, 66, ...

What is the correlation observed in cohen's paper?

0.61

540

[ "ACTOS", "FDA", "Response", "Meeting", "August", "12-13,", "2002", "Page", "4", "of", "4", "Highlights", "from", "Cohen", "Hypothesis", "Discussion", ">", "Philip", "Collett", "presented", "an", "outline", "of", "the", "Cohen", "hypothesis", "Male", "rat", "ur...

[ [ 654, 43, 693, 55 ], [ 695, 43, 720, 54 ], [ 722, 43, 777, 54 ], [ 780, 44, 824, 55 ], [ 713, 55, 754, 65 ], [ 757, 55, 795, 65 ], [ 797, 55, 825, 65 ], [ 760, 66, ...

Why didn't rats eliminate calculi as humans do?

Because rats are quadropeds

547

[ "Minutes", "from", "Takeda", "Global", "Risk", "Management", "Forum/March", "22,", "2004", "Facilitators:", "Glyn", "Belcher,", "MA,", "PhD,", "MB,", "BCHIR,", "FFPM/", "TEuRD", "Cal", "McNeill,", "MD/", "TGRD", "Attendees:", "Mondira", "Bhattacharya", "MD,", "Dav...

[ [ 214, 145, 282, 159 ], [ 285, 145, 322, 160 ], [ 332, 145, 392, 160 ], [ 395, 145, 450, 161 ], [ 454, 145, 491, 161 ], [ 494, 144, 603, 161 ], [ 606, 144, 722, 160 ], [ 72...

What is the fullform of MAA?

Marketing Authorization Application

547

[ "Minutes", "from", "Takeda", "Global", "Risk", "Management", "Forum/March", "22,", "2004", "Facilitators:", "Glyn", "Belcher,", "MA,", "PhD,", "MB,", "BCHIR,", "FFPM/", "TEuRD", "Cal", "McNeill,", "MD/", "TGRD", "Attendees:", "Mondira", "Bhattacharya", "MD,", "Dav...

[ [ 214, 145, 282, 159 ], [ 285, 145, 322, 160 ], [ 332, 145, 392, 160 ], [ 395, 145, 450, 161 ], [ 454, 145, 491, 161 ], [ 494, 144, 603, 161 ], [ 606, 144, 722, 160 ], [ 72...

Which forum is mentioned in this document?

Takeda Global Risk Management Forum

542

[ "107", "FDA", "Conference", "Call:", "August", "13,", "2002", "PENGAD", "800-631-698", "EXHIBIT", "FDA", "Personnel:", "Jeri", "El-Hage,", "Ph.D.,", "Toxicology", "Team", "Leader", "Jena", "Weber,", "Project", "Manager", "TPNA", "Personnel:", "David", "Baron,", "P...

[ [ 785, 93, 849, 115 ], [ 170, 120, 206, 133 ], [ 211, 120, 304, 134 ], [ 307, 120, 350, 135 ], [ 355, 120, 413, 135 ], [ 417, 120, 440, 135 ], [ 442, 119, 481, 135 ], [ 728...

What is the issued date of this document?

august 13, 2002

542

[ "107", "FDA", "Conference", "Call:", "August", "13,", "2002", "PENGAD", "800-631-698", "EXHIBIT", "FDA", "Personnel:", "Jeri", "El-Hage,", "Ph.D.,", "Toxicology", "Team", "Leader", "Jena", "Weber,", "Project", "Manager", "TPNA", "Personnel:", "David", "Baron,", "P...

[ [ 785, 93, 849, 115 ], [ 170, 120, 206, 133 ], [ 211, 120, 304, 134 ], [ 307, 120, 350, 135 ], [ 355, 120, 413, 135 ], [ 417, 120, 440, 135 ], [ 442, 119, 481, 135 ], [ 728...

Who is the Director of Nonclinical Safety and Efficacy?

David baron

542

[ "107", "FDA", "Conference", "Call:", "August", "13,", "2002", "PENGAD", "800-631-698", "EXHIBIT", "FDA", "Personnel:", "Jeri", "El-Hage,", "Ph.D.,", "Toxicology", "Team", "Leader", "Jena", "Weber,", "Project", "Manager", "TPNA", "Personnel:", "David", "Baron,", "P...

[ [ 785, 93, 849, 115 ], [ 170, 120, 206, 133 ], [ 211, 120, 304, 134 ], [ 307, 120, 350, 135 ], [ 355, 120, 413, 135 ], [ 417, 120, 440, 135 ], [ 442, 119, 481, 135 ], [ 728...

Who described tumor promoter-model study?

dr. el-hage

542

[ "107", "FDA", "Conference", "Call:", "August", "13,", "2002", "PENGAD", "800-631-698", "EXHIBIT", "FDA", "Personnel:", "Jeri", "El-Hage,", "Ph.D.,", "Toxicology", "Team", "Leader", "Jena", "Weber,", "Project", "Manager", "TPNA", "Personnel:", "David", "Baron,", "P...

[ [ 785, 93, 849, 115 ], [ 170, 120, 206, 133 ], [ 211, 120, 304, 134 ], [ 307, 120, 350, 135 ], [ 355, 120, 413, 135 ], [ 417, 120, 440, 135 ], [ 442, 119, 481, 135 ], [ 728...

What is the duration of daily dosing?

32-weeks

541

[ "ACTOS", "FDA", "Response", "Meeting", "August", "12-13,", "2002", "Page", "2", "of", "4", "Summary", "of", "July", "31", "Teleconference", "with", "FDA", "(J.", "Haskins)", "-", "Continued", ">", "The", "group", "summarized", "the", "FDA's", "concerns", "as...

[ [ 654, 43, 692, 55 ], [ 695, 43, 720, 54 ], [ 722, 43, 777, 54 ], [ 780, 44, 824, 55 ], [ 714, 55, 754, 66 ], [ 757, 55, 794, 65 ], [ 797, 55, 824, 65 ], [ 760, 66, ...

Who updated the CEO on August 6?

Mr. Saito

541

[ "ACTOS", "FDA", "Response", "Meeting", "August", "12-13,", "2002", "Page", "2", "of", "4", "Summary", "of", "July", "31", "Teleconference", "with", "FDA", "(J.", "Haskins)", "-", "Continued", ">", "The", "group", "summarized", "the", "FDA's", "concerns", "as...

[ [ 654, 43, 692, 55 ], [ 695, 43, 720, 54 ], [ 722, 43, 777, 54 ], [ 780, 44, 824, 55 ], [ 714, 55, 754, 66 ], [ 757, 55, 794, 65 ], [ 797, 55, 824, 65 ], [ 760, 66, ...

By when should TPNA send outline of response to TCI ?

August 19

541

[ "ACTOS", "FDA", "Response", "Meeting", "August", "12-13,", "2002", "Page", "2", "of", "4", "Summary", "of", "July", "31", "Teleconference", "with", "FDA", "(J.", "Haskins)", "-", "Continued", ">", "The", "group", "summarized", "the", "FDA's", "concerns", "as...

[ [ 654, 43, 692, 55 ], [ 695, 43, 720, 54 ], [ 722, 43, 777, 54 ], [ 780, 44, 824, 55 ], [ 714, 55, 754, 66 ], [ 757, 55, 794, 65 ], [ 797, 55, 824, 65 ], [ 760, 66, ...

When will Mr. Saito present outline to CEO?

August 20

541

[ "ACTOS", "FDA", "Response", "Meeting", "August", "12-13,", "2002", "Page", "2", "of", "4", "Summary", "of", "July", "31", "Teleconference", "with", "FDA", "(J.", "Haskins)", "-", "Continued", ">", "The", "group", "summarized", "the", "FDA's", "concerns", "as...

[ [ 654, 43, 692, 55 ], [ 695, 43, 720, 54 ], [ 722, 43, 777, 54 ], [ 780, 44, 824, 55 ], [ 714, 55, 754, 66 ], [ 757, 55, 794, 65 ], [ 797, 55, 824, 65 ], [ 760, 66, ...

By when will the document be finalized?

August 26

545

[ "PENGAD", "BOO-631-698", "EXHIBIT", "102", "FDA", "Conference", "Call", "on", "July", "31,", "2002", "TPNA", "Personnel:", "Wendell", "Cheatham,", "M.D.", "Vice", "President,", "of", "Medial", "and", "Scientific", "Affairs", "Michael", "Elisseou,", "Ph.D.,", "Dire...

[ [ 814, 80, 828, 107 ], [ 815, 45, 830, 79 ], [ 868, 41, 919, 53 ], [ 874, 63, 928, 88 ], [ 344, 134, 382, 150 ], [ 385, 134, 474, 150 ], [ 478, 135, 510, 150 ], [ 514, ...

When will the FDA Conference Call be held?

July 31, 2002

548

[ "Task", "Notes", "Lead", "Responsibility", "Due", "Date", "8.", "COMPETITIVE", "INTELLIGENCE", "Update", "team", "on", "competitive", "Wendell", "Cheatham", "intelligence", "To", "Ongoing", "-", "update", "provided", "at", "each", "meeting", "9.", "Q&", "A", "SH...

[ [ 174, 100, 206, 113 ], [ 386, 101, 438, 114 ], [ 536, 101, 576, 115 ], [ 580, 101, 704, 116 ], [ 769, 101, 807, 115 ], [ 810, 101, 849, 115 ], [ 89, 122, 104, 135 ], [ 107...

When was this document last updated?

August 1, 2002

548

[ "Task", "Notes", "Lead", "Responsibility", "Due", "Date", "8.", "COMPETITIVE", "INTELLIGENCE", "Update", "team", "on", "competitive", "Wendell", "Cheatham", "intelligence", "To", "Ongoing", "-", "update", "provided", "at", "each", "meeting", "9.", "Q&", "A", "SH...

[ [ 174, 100, 206, 113 ], [ 386, 101, 438, 114 ], [ 536, 101, 576, 115 ], [ 580, 101, 704, 116 ], [ 769, 101, 807, 115 ], [ 810, 101, 849, 115 ], [ 89, 122, 104, 135 ], [ 107...

What is the last point in the table?

Evaluate Impact on Tak-559

548

[ "Task", "Notes", "Lead", "Responsibility", "Due", "Date", "8.", "COMPETITIVE", "INTELLIGENCE", "Update", "team", "on", "competitive", "Wendell", "Cheatham", "intelligence", "To", "Ongoing", "-", "update", "provided", "at", "each", "meeting", "9.", "Q&", "A", "SH...

[ [ 174, 100, 206, 113 ], [ 386, 101, 438, 114 ], [ 536, 101, 576, 115 ], [ 580, 101, 704, 116 ], [ 769, 101, 807, 115 ], [ 810, 101, 849, 115 ], [ 89, 122, 104, 135 ], [ 107...

What is the Draft's Due Date?

August 5

501

[ "Dr.", "Tan", "January", "14,", "1999", "Page", "5", "ELI", "LILLY", "AND", "COMPANY", "COMPENSATION", "AND", "BENEFITS", "PROGRAM", "(CONTINUED)", "Additional", "Company", "Benefits", "Medical", "and", "Dental", "Insurance", "Prescription", "Drug", "Benefits", "R...

[ [ 146, 110, 174, 124 ], [ 176, 111, 204, 124 ], [ 146, 126, 207, 140 ], [ 211, 126, 235, 140 ], [ 238, 126, 276, 139 ], [ 146, 143, 184, 156 ], [ 188, 143, 196, 156 ], [ 35...

Which benefit start after 1 year of service?

Extended Disability

543

[ "Ms.", "Wakamatsu,", "Assistant", "manager,", "Dept.", "Strategic", "Development,", "et", "al.", "Attachment:", "NDA", "schedule", "for", "each", "project", "approved", "on", "the", "5th", "GDC", "1.", "Openings", "Remarks", "Dr.", "Kitazawa", "made", "opening", ...

[ [ 107, 142, 132, 152 ], [ 134, 142, 218, 152 ], [ 220, 142, 280, 153 ], [ 282, 142, 346, 153 ], [ 348, 142, 385, 153 ], [ 387, 142, 446, 153 ], [ 448, 141, 540, 153 ], [ 54...

What is Ms Wakamatsu's role in Dept. Strategic Development?

Assistant manager

526

[ "08/07/2002", "18:47", "06", "6204", "2244", ".", "2002'", "08/08", "21:50", "FAX", "06", "6204", "2244", "TAKEDA", "DEVELOP", "DIVISION", "2", "006/006", "6", "/", "6", "Discussion", "points", "to", "address", "the", "three", "key", "issues", "raised", "b...

[ [ 58, 11, 152, 21 ], [ 181, 10, 228, 21 ], [ 272, 10, 291, 21 ], [ 299, 10, 339, 21 ], [ 346, 11, 384, 21 ], [ 31, 21, 39, 31 ], [ 41, 21, 84, 31 ], [ 87, 21, 133, ...

Which drug's toxicity study results will be discussed ?

pioglitazone

535

[ "Task", "Notes", "Lead", "Responsibility", "Due", "Date", "4.", "PEDIATRIC", "STUDIES", "(CONTINUED)", "Evaluate", "data", "from", "Actos", "507", ">", "Evaluate", "data", "to", "support", "Amy", "Hagaman", "August", "5", "ustification", "to", "proceed", "with",...

[ [ 174, 101, 207, 115 ], [ 385, 101, 437, 115 ], [ 534, 101, 576, 116 ], [ 580, 101, 705, 117 ], [ 768, 102, 805, 116 ], [ 808, 103, 850, 116 ], [ 90, 122, 104, 135 ], [ 107...

How many pages are there in total as part of this document?

7

540

[ "ACTOS", "FDA", "Response", "Meeting", "August", "12-13,", "2002", "Page", "4", "of", "4", "Highlights", "from", "Cohen", "Hypothesis", "Discussion", ">", "Philip", "Collett", "presented", "an", "outline", "of", "the", "Cohen", "hypothesis", "Male", "rat", "ur...

[ [ 654, 43, 693, 55 ], [ 695, 43, 720, 54 ], [ 722, 43, 777, 54 ], [ 780, 44, 824, 55 ], [ 713, 55, 754, 65 ], [ 757, 55, 795, 65 ], [ 797, 55, 825, 65 ], [ 760, 66, ...

Who challenged authorities regrading implementing monitoring plan?

Takeda Europe

540

[ "ACTOS", "FDA", "Response", "Meeting", "August", "12-13,", "2002", "Page", "4", "of", "4", "Highlights", "from", "Cohen", "Hypothesis", "Discussion", ">", "Philip", "Collett", "presented", "an", "outline", "of", "the", "Cohen", "hypothesis", "Male", "rat", "ur...

[ [ 654, 43, 693, 55 ], [ 695, 43, 720, 54 ], [ 722, 43, 777, 54 ], [ 780, 44, 824, 55 ], [ 713, 55, 754, 65 ], [ 757, 55, 795, 65 ], [ 797, 55, 825, 65 ], [ 760, 66, ...

What content is high in male rat urine?

protein

550

[ "ACTOS", "FDA", "RESPONSE", "MEETING", "TPNA/TEUR&D/TCI", "AUGUST", "12-13,", "2002", "Attendees:", "TPNA", "TEUR&D", "Sam", "Hamanaka", "David", "Eckland", "Claire", "Thom", "Yasuhiko", "Wada", "Ingrid", "Hood", "Glyn", "Belcher", "Alfonso", "Perez", "Philip", "C...

[ [ 197, 92, 332, 122 ], [ 340, 92, 420, 122 ], [ 432, 92, 612, 122 ], [ 620, 93, 776, 122 ], [ 327, 131, 650, 159 ], [ 373, 164, 456, 183 ], [ 460, 164, 534, 184 ], [ 538, ...

What kind of meeting is mentioned in this letter?

ACTOS FDA RESPONSE MEETING

550

[ "ACTOS", "FDA", "RESPONSE", "MEETING", "TPNA/TEUR&D/TCI", "AUGUST", "12-13,", "2002", "Attendees:", "TPNA", "TEUR&D", "Sam", "Hamanaka", "David", "Eckland", "Claire", "Thom", "Yasuhiko", "Wada", "Ingrid", "Hood", "Glyn", "Belcher", "Alfonso", "Perez", "Philip", "C...

[ [ 197, 92, 332, 122 ], [ 340, 92, 420, 122 ], [ 432, 92, 612, 122 ], [ 620, 93, 776, 122 ], [ 327, 131, 650, 159 ], [ 373, 164, 456, 183 ], [ 460, 164, 534, 184 ], [ 538, ...

what kind of drug is used to treat the group of rats?

Pioglitazone

552

[ "ACTOS", "FDA", "Response", "Meeting", "August", "12-13,", "2002", "Page", "3", "of", "4", "Highlights/", "Discussion", "Points", "from", "Preclinical", "Data", "Presentation", "In", "the", "rat", "oncogenicity", "study,", "thickening", "of", "the", "bladder", "...

[ [ 654, 43, 692, 55 ], [ 695, 43, 720, 54 ], [ 723, 43, 777, 54 ], [ 780, 44, 824, 55 ], [ 714, 55, 754, 66 ], [ 757, 54, 795, 65 ], [ 797, 54, 824, 66 ], [ 760, 66, ...

In the rat oncogenicity study, what was observed in male rats?

thickening of the bladder and hypertrophy of the urothelium

551

[ "Task", "Notes", "Lead", "Responsibility", "Due", "Date", "6.", "INTRODUCTORY/CONCLUSION", "STATEMENTS", "(CONTINUED)", "Send", "nonclinical", "David", "Baron", "August", "20", "rationale/justification", "section", "to", "medical", "writing", "for", "compilation", "Comp...

[ [ 175, 100, 211, 113 ], [ 389, 102, 440, 114 ], [ 536, 102, 578, 116 ], [ 582, 102, 706, 117 ], [ 772, 103, 808, 116 ], [ 813, 104, 854, 116 ], [ 91, 123, 106, 135 ], [ 109...

What is the due date to conduct review meeting for FDA package?

August 22

552

[ "ACTOS", "FDA", "Response", "Meeting", "August", "12-13,", "2002", "Page", "3", "of", "4", "Highlights/", "Discussion", "Points", "from", "Preclinical", "Data", "Presentation", "In", "the", "rat", "oncogenicity", "study,", "thickening", "of", "the", "bladder", "...

[ [ 654, 43, 692, 55 ], [ 695, 43, 720, 54 ], [ 723, 43, 777, 54 ], [ 780, 44, 824, 55 ], [ 714, 55, 754, 66 ], [ 757, 54, 795, 65 ], [ 797, 54, 824, 66 ], [ 760, 66, ...

What is the time span where no tumors are seen?

shorter term (12 month)

551

[ "Task", "Notes", "Lead", "Responsibility", "Due", "Date", "6.", "INTRODUCTORY/CONCLUSION", "STATEMENTS", "(CONTINUED)", "Send", "nonclinical", "David", "Baron", "August", "20", "rationale/justification", "section", "to", "medical", "writing", "for", "compilation", "Comp...

[ [ 175, 100, 211, 113 ], [ 389, 102, 440, 114 ], [ 536, 102, 578, 116 ], [ 582, 102, 706, 117 ], [ 772, 103, 808, 116 ], [ 813, 104, 854, 116 ], [ 91, 123, 106, 135 ], [ 109...

Who is the lead responsible person for the compilation of FDA package?

Larry Hancock

552

[ "ACTOS", "FDA", "Response", "Meeting", "August", "12-13,", "2002", "Page", "3", "of", "4", "Highlights/", "Discussion", "Points", "from", "Preclinical", "Data", "Presentation", "In", "the", "rat", "oncogenicity", "study,", "thickening", "of", "the", "bladder", "...

[ [ 654, 43, 692, 55 ], [ 695, 43, 720, 54 ], [ 723, 43, 777, 54 ], [ 780, 44, 824, 55 ], [ 714, 55, 754, 66 ], [ 757, 54, 795, 65 ], [ 797, 54, 824, 66 ], [ 760, 66, ...

According to mouse oncogenicity study, what was seen male mice only?

hyperplasia

550

[ "ACTOS", "FDA", "RESPONSE", "MEETING", "TPNA/TEUR&D/TCI", "AUGUST", "12-13,", "2002", "Attendees:", "TPNA", "TEUR&D", "Sam", "Hamanaka", "David", "Eckland", "Claire", "Thom", "Yasuhiko", "Wada", "Ingrid", "Hood", "Glyn", "Belcher", "Alfonso", "Perez", "Philip", "C...

[ [ 197, 92, 332, 122 ], [ 340, 92, 420, 122 ], [ 432, 92, 612, 122 ], [ 620, 93, 776, 122 ], [ 327, 131, 650, 159 ], [ 373, 164, 456, 183 ], [ 460, 164, 534, 184 ], [ 538, ...

what kind of cell tumours experienced the same frequency when group of rats treated with pioglitazone?

transitional

552

[ "ACTOS", "FDA", "Response", "Meeting", "August", "12-13,", "2002", "Page", "3", "of", "4", "Highlights/", "Discussion", "Points", "from", "Preclinical", "Data", "Presentation", "In", "the", "rat", "oncogenicity", "study,", "thickening", "of", "the", "bladder", "...

[ [ 654, 43, 692, 55 ], [ 695, 43, 720, 54 ], [ 723, 43, 777, 54 ], [ 780, 44, 824, 55 ], [ 714, 55, 754, 66 ], [ 757, 54, 795, 65 ], [ 797, 54, 824, 66 ], [ 760, 66, ...

who conducted robust program?

TCI

551

[ "Task", "Notes", "Lead", "Responsibility", "Due", "Date", "6.", "INTRODUCTORY/CONCLUSION", "STATEMENTS", "(CONTINUED)", "Send", "nonclinical", "David", "Baron", "August", "20", "rationale/justification", "section", "to", "medical", "writing", "for", "compilation", "Comp...

[ [ 175, 100, 211, 113 ], [ 389, 102, 440, 114 ], [ 536, 102, 578, 116 ], [ 582, 102, 706, 117 ], [ 772, 103, 808, 116 ], [ 813, 104, 854, 116 ], [ 91, 123, 106, 135 ], [ 109...

What is the task assigned to David Baron?

Send nonclinical rationale/justification section to medical writing for compilation

551

[ "Task", "Notes", "Lead", "Responsibility", "Due", "Date", "6.", "INTRODUCTORY/CONCLUSION", "STATEMENTS", "(CONTINUED)", "Send", "nonclinical", "David", "Baron", "August", "20", "rationale/justification", "section", "to", "medical", "writing", "for", "compilation", "Comp...

[ [ 175, 100, 211, 113 ], [ 389, 102, 440, 114 ], [ 536, 102, 578, 116 ], [ 582, 102, 706, 117 ], [ 772, 103, 808, 116 ], [ 813, 104, 854, 116 ], [ 91, 123, 106, 135 ], [ 109...

Who is responsible for sending package to TCI/EU for review?

Mary Ramstack

551

[ "Task", "Notes", "Lead", "Responsibility", "Due", "Date", "6.", "INTRODUCTORY/CONCLUSION", "STATEMENTS", "(CONTINUED)", "Send", "nonclinical", "David", "Baron", "August", "20", "rationale/justification", "section", "to", "medical", "writing", "for", "compilation", "Comp...

[ [ 175, 100, 211, 113 ], [ 389, 102, 440, 114 ], [ 536, 102, 578, 116 ], [ 582, 102, 706, 117 ], [ 772, 103, 808, 116 ], [ 813, 104, 854, 116 ], [ 91, 123, 106, 135 ], [ 109...

What is the due date for sending FDA Document to Regulatory Affairs?

August 26

551

[ "Task", "Notes", "Lead", "Responsibility", "Due", "Date", "6.", "INTRODUCTORY/CONCLUSION", "STATEMENTS", "(CONTINUED)", "Send", "nonclinical", "David", "Baron", "August", "20", "rationale/justification", "section", "to", "medical", "writing", "for", "compilation", "Comp...

[ [ 175, 100, 211, 113 ], [ 389, 102, 440, 114 ], [ 536, 102, 578, 116 ], [ 582, 102, 706, 117 ], [ 772, 103, 808, 116 ], [ 813, 104, 854, 116 ], [ 91, 123, 106, 135 ], [ 109...

What is the last updated date mentioned in this document?

August 1, 2002

554

[ "Horizon", "-", "ACTOS", "PRODUCTS", "LIABILITY", "CLAIMS", "Page", "1", "of", "2", "Home", "News", "&", "Events", "People", "Workplace", "&", "Services", "Culture", "&", "Values", "Tools", "&", "Resources", "Team", "Horton", "ACTOS", "PRODUCTS", "LIABILITY", ...

[ [ 125, 39, 187, 54 ], [ 191, 40, 198, 54 ], [ 202, 40, 263, 55 ], [ 267, 40, 366, 55 ], [ 370, 39, 464, 55 ], [ 468, 38, 541, 55 ], [ 824, 40, 862, 55 ], [ 866, 40, ...

Which product's liability claims are described here?

ACTOS PRODUCTS

554

[ "Horizon", "-", "ACTOS", "PRODUCTS", "LIABILITY", "CLAIMS", "Page", "1", "of", "2", "Home", "News", "&", "Events", "People", "Workplace", "&", "Services", "Culture", "&", "Values", "Tools", "&", "Resources", "Team", "Horton", "ACTOS", "PRODUCTS", "LIABILITY", ...

[ [ 125, 39, 187, 54 ], [ 191, 40, 198, 54 ], [ 202, 40, 263, 55 ], [ 267, 40, 366, 55 ], [ 370, 39, 464, 55 ], [ 468, 38, 541, 55 ], [ 824, 40, 862, 55 ], [ 866, 40, ...

What is the date mentioned in this document at the bottom?

1/11/2007

553

[ "PROactive'", "Executive", "Committee", "Conference", "Call", "Minutes", "of", "Conference", "Call", "Date:", "Monday", "28\"", "November", "2005", "EXHIBIT", "NO.", "Time:", "1900", "hours", "In", "attendance:", "Professor", "Erland", "Erdmann", "(EE)", "rmandy", ...

[ [ 220, 103, 413, 125 ], [ 470, 105, 569, 122 ], [ 573, 105, 681, 122 ], [ 686, 104, 800, 122 ], [ 805, 104, 844, 122 ], [ 440, 166, 496, 178 ], [ 498, 167, 513, 178 ], [ 51...

Mention the first name listed in the "apologies"?

Professor Ele Ferrannini

554

[ "Horizon", "-", "ACTOS", "PRODUCTS", "LIABILITY", "CLAIMS", "Page", "1", "of", "2", "Home", "News", "&", "Events", "People", "Workplace", "&", "Services", "Culture", "&", "Values", "Tools", "&", "Resources", "Team", "Horton", "ACTOS", "PRODUCTS", "LIABILITY", ...

[ [ 125, 39, 187, 54 ], [ 191, 40, 198, 54 ], [ 202, 40, 263, 55 ], [ 267, 40, 366, 55 ], [ 370, 39, 464, 55 ], [ 468, 38, 541, 55 ], [ 824, 40, 862, 55 ], [ 866, 40, ...

What is the exhibit number?

52

553

[ "PROactive'", "Executive", "Committee", "Conference", "Call", "Minutes", "of", "Conference", "Call", "Date:", "Monday", "28\"", "November", "2005", "EXHIBIT", "NO.", "Time:", "1900", "hours", "In", "attendance:", "Professor", "Erland", "Erdmann", "(EE)", "rmandy", ...

[ [ 220, 103, 413, 125 ], [ 470, 105, 569, 122 ], [ 573, 105, 681, 122 ], [ 686, 104, 800, 122 ], [ 805, 104, 844, 122 ], [ 440, 166, 496, 178 ], [ 498, 167, 513, 178 ], [ 51...

when was the last meeting/conference call held on ?

15th October 2005

542

[ "107", "FDA", "Conference", "Call:", "August", "13,", "2002", "PENGAD", "800-631-698", "EXHIBIT", "FDA", "Personnel:", "Jeri", "El-Hage,", "Ph.D.,", "Toxicology", "Team", "Leader", "Jena", "Weber,", "Project", "Manager", "TPNA", "Personnel:", "David", "Baron,", "P...

[ [ 785, 93, 849, 115 ], [ 170, 120, 206, 133 ], [ 211, 120, 304, 134 ], [ 307, 120, 350, 135 ], [ 355, 120, 413, 135 ], [ 417, 120, 440, 135 ], [ 442, 119, 481, 135 ], [ 728...

What is the exhibit number?

107

553

[ "PROactive'", "Executive", "Committee", "Conference", "Call", "Minutes", "of", "Conference", "Call", "Date:", "Monday", "28\"", "November", "2005", "EXHIBIT", "NO.", "Time:", "1900", "hours", "In", "attendance:", "Professor", "Erland", "Erdmann", "(EE)", "rmandy", ...

[ [ 220, 103, 413, 125 ], [ 470, 105, 569, 122 ], [ 573, 105, 681, 122 ], [ 686, 104, 800, 122 ], [ 805, 104, 844, 122 ], [ 440, 166, 496, 178 ], [ 498, 167, 513, 178 ], [ 51...

what is the date mentioned under the title - " minutes of conference call"?

Monday 28th November 2005

558

[ "Rationale", "for", "3", "Segments", "actos", "pioglitazone", "HCI", "For", "performance", "that", "benefits", "the", "body.", "Summary", "of", "Segment", "Attractiveness", "(based", "on", "current", "situation", "&", "future", "trends)", "Treatment", "Machines,", ...

[ [ 93, 134, 279, 188 ], [ 290, 134, 349, 190 ], [ 355, 134, 381, 190 ], [ 392, 134, 590, 195 ], [ 784, 104, 941, 151 ], [ 782, 147, 904, 179 ], [ 908, 145, 945, 176 ], [ 783...

What is the heading of this document?

Rationale for 3 segments

556

[ "(2)", "The", "person", "in", "charge", "of", "storage", "shall", "properly", "store,", "and", "dispose", "of,", "any", "stored", "documents", "assigned,", "and", "properly", "store", "any", "records", "relevant", "to", "those", "storage", "and", "disposal.", ...

[ [ 130, 118, 158, 133 ], [ 162, 118, 188, 133 ], [ 191, 118, 240, 134 ], [ 243, 118, 259, 134 ], [ 262, 118, 311, 134 ], [ 314, 118, 328, 134 ], [ 332, 118, 384, 134 ], [ 38...

what is the title of chapter 3?

Document Storage Period

558

[ "Rationale", "for", "3", "Segments", "actos", "pioglitazone", "HCI", "For", "performance", "that", "benefits", "the", "body.", "Summary", "of", "Segment", "Attractiveness", "(based", "on", "current", "situation", "&", "future", "trends)", "Treatment", "Machines,", ...

[ [ 93, 134, 279, 188 ], [ 290, 134, 349, 190 ], [ 355, 134, 381, 190 ], [ 392, 134, 590, 195 ], [ 784, 104, 941, 151 ], [ 782, 147, 904, 179 ], [ 908, 145, 945, 176 ], [ 783...

What is the graphical representation about?

Summary of Segment Attractiveness

558

[ "Rationale", "for", "3", "Segments", "actos", "pioglitazone", "HCI", "For", "performance", "that", "benefits", "the", "body.", "Summary", "of", "Segment", "Attractiveness", "(based", "on", "current", "situation", "&", "future", "trends)", "Treatment", "Machines,", ...

[ [ 93, 134, 279, 188 ], [ 290, 134, 349, 190 ], [ 355, 134, 381, 190 ], [ 392, 134, 590, 195 ], [ 784, 104, 941, 151 ], [ 782, 147, 904, 179 ], [ 908, 145, 945, 176 ], [ 783...

On what basis, the Summary of Segment Attractiveness is carried out?

based on current situation & future trends

558

[ "Rationale", "for", "3", "Segments", "actos", "pioglitazone", "HCI", "For", "performance", "that", "benefits", "the", "body.", "Summary", "of", "Segment", "Attractiveness", "(based", "on", "current", "situation", "&", "future", "trends)", "Treatment", "Machines,", ...

[ [ 93, 134, 279, 188 ], [ 290, 134, 349, 190 ], [ 355, 134, 381, 190 ], [ 392, 134, 590, 195 ], [ 784, 104, 941, 151 ], [ 782, 147, 904, 179 ], [ 908, 145, 945, 176 ], [ 783...

What are the three segments indicated in the graph?

Treatment Machines, Life Negotiators, Struggle for Control

556

[ "(2)", "The", "person", "in", "charge", "of", "storage", "shall", "properly", "store,", "and", "dispose", "of,", "any", "stored", "documents", "assigned,", "and", "properly", "store", "any", "records", "relevant", "to", "those", "storage", "and", "disposal.", ...

[ [ 130, 118, 158, 133 ], [ 162, 118, 188, 133 ], [ 191, 118, 240, 134 ], [ 243, 118, 259, 134 ], [ 262, 118, 311, 134 ], [ 314, 118, 328, 134 ], [ 332, 118, 384, 134 ], [ 38...

what is the "document storage period " article number?

7

558

[ "Rationale", "for", "3", "Segments", "actos", "pioglitazone", "HCI", "For", "performance", "that", "benefits", "the", "body.", "Summary", "of", "Segment", "Attractiveness", "(based", "on", "current", "situation", "&", "future", "trends)", "Treatment", "Machines,", ...

[ [ 93, 134, 279, 188 ], [ 290, 134, 349, 190 ], [ 355, 134, 381, 190 ], [ 392, 134, 590, 195 ], [ 784, 104, 941, 151 ], [ 782, 147, 904, 179 ], [ 908, 145, 945, 176 ], [ 783...

What is the conclusion obtained from the graph?

All 3 segments have consistent needs

556

[ "(2)", "The", "person", "in", "charge", "of", "storage", "shall", "properly", "store,", "and", "dispose", "of,", "any", "stored", "documents", "assigned,", "and", "properly", "store", "any", "records", "relevant", "to", "those", "storage", "and", "disposal.", ...

[ [ 130, 118, 158, 133 ], [ 162, 118, 188, 133 ], [ 191, 118, 240, 134 ], [ 243, 118, 259, 134 ], [ 262, 118, 311, 134 ], [ 314, 118, 328, 134 ], [ 332, 118, 384, 134 ], [ 38...

mention the second point listed under the article 7(document storage period)?

To be stored for ten years

557

[ "3)", "Other", "places", "designated", "by", "the", "relevant", "core", "organizations", ".", "\"Responsible", "person", "in", "charge", "of", "storage\"", "shall", "mean", "the", "responsible", "person", "in", "charge", "of", "a", "core", "organization.", "5.",...

[ [ 188, 118, 212, 134 ], [ 223, 118, 264, 134 ], [ 267, 118, 317, 135 ], [ 320, 119, 392, 135 ], [ 396, 119, 415, 135 ], [ 418, 119, 441, 135 ], [ 445, 119, 503, 135 ], [ 50...

what is article 4?

(PRINCIPLES OF CREATING DOCUMENTS)

580

[ "Summary", "of", "Terms", "for", "OUS", "Agreement", "License", "Exclusive", "rights", "in", "approximately", "60", "countries", "Semi", "exclusive", "rights", "in", "approximately", "20", "countries", "Upfront", "Fee", "$20", "million", "signing", "fee", "with", ...

[ [ 251, 182, 338, 198 ], [ 342, 182, 362, 197 ], [ 366, 182, 420, 197 ], [ 424, 182, 450, 197 ], [ 453, 182, 495, 197 ], [ 499, 182, 595, 199 ], [ 281, 201, 337, 214 ], [ 28...

Semi exclusive rights in how many countries?

20

557

[ "3)", "Other", "places", "designated", "by", "the", "relevant", "core", "organizations", ".", "\"Responsible", "person", "in", "charge", "of", "storage\"", "shall", "mean", "the", "responsible", "person", "in", "charge", "of", "a", "core", "organization.", "5.",...

[ [ 188, 118, 212, 134 ], [ 223, 118, 264, 134 ], [ 267, 118, 317, 135 ], [ 320, 119, 392, 135 ], [ 396, 119, 415, 135 ], [ 418, 119, 441, 135 ], [ 445, 119, 503, 135 ], [ 50...

what is the title of chapter 2?

DOCUMENT STORAGE FUNCTIONS

580

[ "Summary", "of", "Terms", "for", "OUS", "Agreement", "License", "Exclusive", "rights", "in", "approximately", "60", "countries", "Semi", "exclusive", "rights", "in", "approximately", "20", "countries", "Upfront", "Fee", "$20", "million", "signing", "fee", "with", ...

[ [ 251, 182, 338, 198 ], [ 342, 182, 362, 197 ], [ 366, 182, 420, 197 ], [ 424, 182, 450, 197 ], [ 453, 182, 495, 197 ], [ 499, 182, 595, 199 ], [ 281, 201, 337, 214 ], [ 28...

What percent is the Supply Price / Royalty Rate?

30% SUPPLY PRICE

557

[ "3)", "Other", "places", "designated", "by", "the", "relevant", "core", "organizations", ".", "\"Responsible", "person", "in", "charge", "of", "storage\"", "shall", "mean", "the", "responsible", "person", "in", "charge", "of", "a", "core", "organization.", "5.",...

[ [ 188, 118, 212, 134 ], [ 223, 118, 264, 134 ], [ 267, 118, 317, 135 ], [ 320, 119, 392, 135 ], [ 396, 119, 415, 135 ], [ 418, 119, 441, 135 ], [ 445, 119, 503, 135 ], [ 50...

What does article 5 in this document describes?

(principles concerning document storage functions)

557

[ "3)", "Other", "places", "designated", "by", "the", "relevant", "core", "organizations", ".", "\"Responsible", "person", "in", "charge", "of", "storage\"", "shall", "mean", "the", "responsible", "person", "in", "charge", "of", "a", "core", "organization.", "5.",...

[ [ 188, 118, 212, 134 ], [ 223, 118, 264, 134 ], [ 267, 118, 317, 135 ], [ 320, 119, 392, 135 ], [ 396, 119, 415, 135 ], [ 418, 119, 441, 135 ], [ 445, 119, 503, 135 ], [ 50...

what is article 6?

DUTIES OF RESPONSIBLE PERSON IN CHARGE OF STORAGE AND PERSON IN CHARGE OF STORAGE

580

[ "Summary", "of", "Terms", "for", "OUS", "Agreement", "License", "Exclusive", "rights", "in", "approximately", "60", "countries", "Semi", "exclusive", "rights", "in", "approximately", "20", "countries", "Upfront", "Fee", "$20", "million", "signing", "fee", "with", ...

[ [ 251, 182, 338, 198 ], [ 342, 182, 362, 197 ], [ 366, 182, 420, 197 ], [ 424, 182, 450, 197 ], [ 453, 182, 495, 197 ], [ 499, 182, 595, 199 ], [ 281, 201, 337, 214 ], [ 28...

In how many countires, license to Exclusive rights are provided?

in approximately 60 countries

560

[ "ACTOS", "Pediatric", "Program", "5", "October", "2006", "TAK-TROOSA-00427563", "Source:", "https://www.industrydocu?<", "<-09001", "cuments.ucsf.edu/docs/jfkf0226" ]

[ [ 202, 298, 369, 357 ], [ 388, 298, 588, 362 ], [ 599, 301, 777, 367 ], [ 202, 514, 225, 560 ], [ 235, 514, 388, 560 ], [ 394, 515, 483, 560 ], [ 13, 805, 27, 982 ], [ 290,...

what is the name of pediatric program?

ACTOS

560

[ "ACTOS", "Pediatric", "Program", "5", "October", "2006", "TAK-TROOSA-00427563", "Source:", "https://www.industrydocu?<", "<-09001", "cuments.ucsf.edu/docs/jfkf0226" ]

[ [ 202, 298, 369, 357 ], [ 388, 298, 588, 362 ], [ 599, 301, 777, 367 ], [ 202, 514, 225, 560 ], [ 235, 514, 388, 560 ], [ 394, 515, 483, 560 ], [ 13, 805, 27, 982 ], [ 290,...

What is the date mentioned in this page?

5 October 2006

573

[ "Alex", "OD", "PoRET", "Critical", "Success", "Factors", "actos", "pioglitazone", "HCI", "For", "performance", "that", "benefits", "the", "body", "1.", "Condition", "the", "Market", "on", "IR", "and", "its", "link", "to", "CV", "risk", "including", "lipid", ...

[ [ 808, 77, 843, 95 ], [ 845, 78, 861, 95 ], [ 863, 78, 897, 95 ], [ 81, 131, 250, 191 ], [ 259, 131, 441, 191 ], [ 450, 133, 610, 190 ], [ 806, 93, 938, 140 ], [ 808, 1...

What is the title of this document?

CRITICAL SUCCESS FACTORS

570

[ "Consequences", "of", "IR", "Damage", "to", "Eyes", "Damage", "to", "Kidneys", "HDL-C", "LDL-C", "Damage", "to", "Nerves", "Increased", "CV", "Risk", "Increased", "CV", "Risk", "Hyperglycemia", "Dyslipidemia", "Insulin", "Resistance", "Central", "Obesity", "Hypert...

[ [ 94, 115, 391, 164 ], [ 400, 115, 443, 163 ], [ 450, 114, 490, 161 ], [ 175, 239, 247, 262 ], [ 251, 240, 269, 263 ], [ 274, 240, 316, 263 ], [ 160, 275, 234, 297 ], [ 236...

What is the title of this document?

Consequences of IR

586

[ "TZD", "Share", "of", "Oral", "Market", "%", "Retail", "TRx", "Share", "25%", "Actual", "Forecast", "20%", "15%", "10%", "5%", "0%", "Apr-01", "Jul-01", "Oct-01", "Jan-02", "Apr-02", "1-02", "-03", "Oct-", "Jan", "Apr-03", "Jul-03", "Jan-04", "Apr-04", "Ju...

[ [ 96, 107, 158, 148 ], [ 176, 106, 277, 151 ], [ 288, 106, 329, 151 ], [ 335, 106, 411, 151 ], [ 416, 107, 538, 151 ], [ 96, 195, 108, 219 ], [ 113, 195, 164, 220 ], [ 168,...

What does the graph describes in this document?

TZD SHARE OF ORAL MARKET

586

[ "TZD", "Share", "of", "Oral", "Market", "%", "Retail", "TRx", "Share", "25%", "Actual", "Forecast", "20%", "15%", "10%", "5%", "0%", "Apr-01", "Jul-01", "Oct-01", "Jan-02", "Apr-02", "1-02", "-03", "Oct-", "Jan", "Apr-03", "Jul-03", "Jan-04", "Apr-04", "Ju...

[ [ 96, 107, 158, 148 ], [ 176, 106, 277, 151 ], [ 288, 106, 329, 151 ], [ 335, 106, 411, 151 ], [ 416, 107, 538, 151 ], [ 96, 195, 108, 219 ], [ 113, 195, 164, 220 ], [ 168,...

What is the Plan TZD Share for the year 2003?

19.7%

586

[ "TZD", "Share", "of", "Oral", "Market", "%", "Retail", "TRx", "Share", "25%", "Actual", "Forecast", "20%", "15%", "10%", "5%", "0%", "Apr-01", "Jul-01", "Oct-01", "Jan-02", "Apr-02", "1-02", "-03", "Oct-", "Jan", "Apr-03", "Jul-03", "Jan-04", "Apr-04", "Ju...

[ [ 96, 107, 158, 148 ], [ 176, 106, 277, 151 ], [ 288, 106, 329, 151 ], [ 335, 106, 411, 151 ], [ 416, 107, 538, 151 ], [ 96, 195, 108, 219 ], [ 113, 195, 164, 220 ], [ 168,...

Which year has 13.3% Oral share (TZD)?

2000

571

[ "Clinical", "Study", "Synopsis", "01-06-TL-OPI-527", "o", "Expert", "advisory", "meeting", "4", "October", "2006", "o", "Draft", "synopsis", "available", "for", "team", "review", "on", "Monday,", "9", "October", "2006", "o", "Team", "proposing", "to", "review", ...

[ [ 191, 122, 330, 176 ], [ 336, 122, 439, 180 ], [ 450, 122, 609, 180 ], [ 191, 186, 519, 233 ], [ 188, 313, 207, 351 ], [ 224, 312, 332, 354 ], [ 337, 312, 472, 355 ], [ 48...

Which study's synopsis is this?

Clinical Study

571

[ "Clinical", "Study", "Synopsis", "01-06-TL-OPI-527", "o", "Expert", "advisory", "meeting", "4", "October", "2006", "o", "Draft", "synopsis", "available", "for", "team", "review", "on", "Monday,", "9", "October", "2006", "o", "Team", "proposing", "to", "review", ...

[ [ 191, 122, 330, 176 ], [ 336, 122, 439, 180 ], [ 450, 122, 609, 180 ], [ 191, 186, 519, 233 ], [ 188, 313, 207, 351 ], [ 224, 312, 332, 354 ], [ 337, 312, 472, 355 ], [ 48...

what is the code mentioned under the title of clinical study synopsis?

01-06-TL-OPI-527

571

[ "Clinical", "Study", "Synopsis", "01-06-TL-OPI-527", "o", "Expert", "advisory", "meeting", "4", "October", "2006", "o", "Draft", "synopsis", "available", "for", "team", "review", "on", "Monday,", "9", "October", "2006", "o", "Team", "proposing", "to", "review", ...

[ [ 191, 122, 330, 176 ], [ 336, 122, 439, 180 ], [ 450, 122, 609, 180 ], [ 191, 186, 519, 233 ], [ 188, 313, 207, 351 ], [ 224, 312, 332, 354 ], [ 337, 312, 472, 355 ], [ 48...

When was expert advisory meeting ?

4 OCTOBER 2006

599

[ "Overview", "of", "November", "2006", "Submission", "o", "PPSR", "(Proposed", "Pediatric", "Study", "Request)", "NEED", "TO", "CONFIRM", "FORMAT", "Clinical", "study", "synopsis", "TAK-TROOSA-00427563", "Source:", "https://www.industrydocuments.ucsf.edu/docs/jfkf0226" ]

[ [ 191, 121, 356, 171 ], [ 370, 121, 409, 171 ], [ 416, 122, 610, 171 ], [ 617, 122, 702, 170 ], [ 192, 185, 398, 233 ], [ 191, 310, 214, 353 ], [ 226, 309, 317, 355 ], [ 33...

What is the title of this document?

OVERVIEW OF NOVEMBER 2006 SUBMISSION

599

[ "Overview", "of", "November", "2006", "Submission", "o", "PPSR", "(Proposed", "Pediatric", "Study", "Request)", "NEED", "TO", "CONFIRM", "FORMAT", "Clinical", "study", "synopsis", "TAK-TROOSA-00427563", "Source:", "https://www.industrydocuments.ucsf.edu/docs/jfkf0226" ]

[ [ 191, 121, 356, 171 ], [ 370, 121, 409, 171 ], [ 416, 122, 610, 171 ], [ 617, 122, 702, 170 ], [ 192, 185, 398, 233 ], [ 191, 310, 214, 353 ], [ 226, 309, 317, 355 ], [ 33...

What is the full form of PPSR?

PROPOSED PEDIATRIC STUDY REQUEST

605

[ "NDA", "21-073/S-023", "Page", "9", "Table", "2", "shows", "HbAy,", "and", "FPG", "values", "for", "the", "entire", "study", "population.", "Table", "2", "Glycemic", "Parameters", "in", "a", "26-Week", "Placebo-Controlled", "Dose-Ranging", "Study", "Placeb", "AC...

[ [ 112, 62, 154, 77 ], [ 158, 62, 258, 77 ], [ 114, 78, 152, 92 ], [ 155, 78, 164, 91 ], [ 118, 108, 158, 120 ], [ 160, 108, 171, 120 ], [ 172, 108, 216, 120 ], [ 219, 1...

What study is described in the table given?

Glycemic Parameters in a 26-Week Placebo-Controlled Dose-Ranging Study.

605

[ "NDA", "21-073/S-023", "Page", "9", "Table", "2", "shows", "HbAy,", "and", "FPG", "values", "for", "the", "entire", "study", "population.", "Table", "2", "Glycemic", "Parameters", "in", "a", "26-Week", "Placebo-Controlled", "Dose-Ranging", "Study", "Placeb", "AC...

[ [ 112, 62, 154, 77 ], [ 158, 62, 258, 77 ], [ 114, 78, 152, 92 ], [ 155, 78, 164, 91 ], [ 118, 108, 158, 120 ], [ 160, 108, 171, 120 ], [ 172, 108, 216, 120 ], [ 219, 1...

Which parameters are considered for the study(see heading of table 2)?

Glycemic Parameters

605

[ "NDA", "21-073/S-023", "Page", "9", "Table", "2", "shows", "HbAy,", "and", "FPG", "values", "for", "the", "entire", "study", "population.", "Table", "2", "Glycemic", "Parameters", "in", "a", "26-Week", "Placebo-Controlled", "Dose-Ranging", "Study", "Placeb", "AC...

[ [ 112, 62, 154, 77 ], [ 158, 62, 258, 77 ], [ 114, 78, 152, 92 ], [ 155, 78, 164, 91 ], [ 118, 108, 158, 120 ], [ 160, 108, 171, 120 ], [ 172, 108, 216, 120 ], [ 219, 1...

Prior to what, the patients entered an 8 week washout/run-in-period?

double-blind treatment

579

[ "Overview", "of", "Major", "Contract", "Terms", "Promotional", "Samples", "At", "Cost", "New", "Indications/Line", "Extension", "Takeda", "must", "offer", "to", "Lilly", "If", "Lilly", "agrees,", "then", "cost", "sharing", "based", "on", "expected", "benefit\"", ...

[ [ 253, 183, 334, 198 ], [ 341, 184, 361, 199 ], [ 364, 184, 415, 199 ], [ 418, 183, 497, 199 ], [ 501, 183, 557, 199 ], [ 237, 207, 331, 221 ], [ 334, 209, 398, 222 ], [ 29...

What is the floor supply price?

$0.17 / 30 mg or Takeda's cost from site of lowest cost

579

[ "Overview", "of", "Major", "Contract", "Terms", "Promotional", "Samples", "At", "Cost", "New", "Indications/Line", "Extension", "Takeda", "must", "offer", "to", "Lilly", "If", "Lilly", "agrees,", "then", "cost", "sharing", "based", "on", "expected", "benefit\"", ...

[ [ 253, 183, 334, 198 ], [ 341, 184, 361, 199 ], [ 364, 184, 415, 199 ], [ 418, 183, 497, 199 ], [ 501, 183, 557, 199 ], [ 237, 207, 331, 221 ], [ 334, 209, 398, 222 ], [ 29...

What is the royalty adjustment if generic enters the market ?

50%

579

[ "Overview", "of", "Major", "Contract", "Terms", "Promotional", "Samples", "At", "Cost", "New", "Indications/Line", "Extension", "Takeda", "must", "offer", "to", "Lilly", "If", "Lilly", "agrees,", "then", "cost", "sharing", "based", "on", "expected", "benefit\"", ...

[ [ 253, 183, 334, 198 ], [ 341, 184, 361, 199 ], [ 364, 184, 415, 199 ], [ 418, 183, 497, 199 ], [ 501, 183, 557, 199 ], [ 237, 207, 331, 221 ], [ 334, 209, 398, 222 ], [ 29...

what is the promotional trails data usage for( Lilly in exclusive) ?

Split of 70/30 (Lilly in Exclusive)

582

[ "CSF's", "and", "Marketing", "Thegys", "Q0", "Power", "actos", "Objectives*", "pioglitazone", "HCI", "For", "performance", "that", "benefits", "the", "body.", "CSF", "#1-", "Condition", "the", "market", "on", "IR", "and", "its", "link", "to", "CV", "risk", "...

[ [ 68, 77, 198, 133 ], [ 205, 77, 290, 135 ], [ 298, 77, 528, 143 ], [ 823, 77, 852, 93 ], [ 854, 77, 869, 93 ], [ 871, 77, 903, 93 ], [ 822, 94, 939, 131 ], [ 63, 151, ...

What is the title mentioned in this document?

CSF'S AND MARKETING OBJECTIVES

579

[ "Overview", "of", "Major", "Contract", "Terms", "Promotional", "Samples", "At", "Cost", "New", "Indications/Line", "Extension", "Takeda", "must", "offer", "to", "Lilly", "If", "Lilly", "agrees,", "then", "cost", "sharing", "based", "on", "expected", "benefit\"", ...

[ [ 253, 183, 334, 198 ], [ 341, 184, 361, 199 ], [ 364, 184, 415, 199 ], [ 418, 183, 497, 199 ], [ 501, 183, 557, 199 ], [ 237, 207, 331, 221 ], [ 334, 209, 398, 222 ], [ 29...

What is the promotional trials data usage for (semi exclusive)?

50/50 in Semi-exclusive

583

[ "Actos", "2004", "Marketing", "Plan", "Review", "DALY", "12", "Lilly", "Answers", "That", "Matter.", "Confidential", "-", "Subject", "to", "Protective", "Order", "LLY-HOVENR-00001895", "Produced", "in", "MDL", "on", "02/27/13", "Source:", "https://www.induposescooouts...

[ [ 270, 315, 383, 363 ], [ 397, 314, 484, 363 ], [ 266, 374, 466, 429 ], [ 473, 375, 562, 429 ], [ 575, 375, 710, 428 ], [ 717, 534, 796, 596 ], [ 802, 531, 840, 589 ], [ 73...

what is the name of the plan review ?

MARKETING PLAN REVIEW

620

[ "ACTOS", "FDA", "Response", "Strategy", "TASK", "FORCE", "-TPNA", "Alfonso", "Perez", "Janet", "Haskins*", "Mary", "Ramstack*", "Ingrid", "Hoos", "Michael", "Elisseou", "John", "Page", "(Rich", "Wilson)", "Claire", "Thom", "Dan", "Orlando", "David", "Baron", "(C...

[ [ 282, 81, 385, 103 ], [ 394, 81, 451, 104 ], [ 460, 82, 585, 105 ], [ 590, 82, 700, 105 ], [ 162, 133, 211, 148 ], [ 217, 134, 281, 148 ], [ 284, 132, 340, 148 ], [ 163, ...

What is the heading of this document?

ACTOS FDA RESPONSE STRATEGY

620

[ "ACTOS", "FDA", "Response", "Strategy", "TASK", "FORCE", "-TPNA", "Alfonso", "Perez", "Janet", "Haskins*", "Mary", "Ramstack*", "Ingrid", "Hoos", "Michael", "Elisseou", "John", "Page", "(Rich", "Wilson)", "Claire", "Thom", "Dan", "Orlando", "David", "Baron", "(C...

[ [ 282, 81, 385, 103 ], [ 394, 81, 451, 104 ], [ 460, 82, 585, 105 ], [ 590, 82, 700, 105 ], [ 162, 133, 211, 148 ], [ 217, 134, 281, 148 ], [ 284, 132, 340, 148 ], [ 163, ...

What is the last revision date mentioned in this document?

August 7, 2002

620

[ "ACTOS", "FDA", "Response", "Strategy", "TASK", "FORCE", "-TPNA", "Alfonso", "Perez", "Janet", "Haskins*", "Mary", "Ramstack*", "Ingrid", "Hoos", "Michael", "Elisseou", "John", "Page", "(Rich", "Wilson)", "Claire", "Thom", "Dan", "Orlando", "David", "Baron", "(C...

[ [ 282, 81, 385, 103 ], [ 394, 81, 451, 104 ], [ 460, 82, 585, 105 ], [ 590, 82, 700, 105 ], [ 162, 133, 211, 148 ], [ 217, 134, 281, 148 ], [ 284, 132, 340, 148 ], [ 163, ...

What is the goal of TPNA?

to supply justification to support maintaining current labeling.

575

[ "Most", "Significant", "Adverse", "Events", "Risks", "for", "Pioglitazone", "Risk", "Onset", "Reversibility", "Clinical", "Findings", "Occurrence", "of", "ALT", "Elevation", "Within", "2", "months", "Only", "through", "Drug", "Placebo", "Liver", "Failure", "Transpla...

[ [ 246, 181, 293, 198 ], [ 297, 181, 392, 198 ], [ 396, 182, 469, 199 ], [ 473, 182, 534, 199 ], [ 538, 182, 588, 199 ], [ 593, 182, 618, 199 ], [ 622, 182, 735, 199 ], [ 25...

what is the first point given in table for bladder cancer alongside of clinical findings ?

OBSERVED DURING PRECLINICAL STUDIES IN RATS

583

[ "Actos", "2004", "Marketing", "Plan", "Review", "DALY", "12", "Lilly", "Answers", "That", "Matter.", "Confidential", "-", "Subject", "to", "Protective", "Order", "LLY-HOVENR-00001895", "Produced", "in", "MDL", "on", "02/27/13", "Source:", "https://www.induposescooouts...

[ [ 270, 315, 383, 363 ], [ 397, 314, 484, 363 ], [ 266, 374, 466, 429 ], [ 473, 375, 562, 429 ], [ 575, 375, 710, 428 ], [ 717, 534, 796, 596 ], [ 802, 531, 840, 589 ], [ 73...

Mention the year given for Actos?

2004

584

[ "Actos", "Share", "of", "TZDs", "Retail", "TRX", "SOM,", "IMS", "Health", "60.00%", "Actual", "Forecast", "50.00%", "40.00%", "Launch", "of", "Launch", "of", "30.00%", "Merck's", "BMS'", "PPAR's", "PPAR's", "Q3", "2005", "20.00%", "Feb", "2005", "10.00%", "0...

[ [ 108, 90, 221, 137 ], [ 234, 89, 351, 138 ], [ 362, 89, 411, 138 ], [ 417, 89, 516, 138 ], [ 106, 197, 156, 220 ], [ 160, 196, 195, 220 ], [ 198, 196, 247, 220 ], [ 250, ...

what is the percentage of TZD share in the year 2000 ?

40.3%

584

[ "Actos", "Share", "of", "TZDs", "Retail", "TRX", "SOM,", "IMS", "Health", "60.00%", "Actual", "Forecast", "50.00%", "40.00%", "Launch", "of", "Launch", "of", "30.00%", "Merck's", "BMS'", "PPAR's", "PPAR's", "Q3", "2005", "20.00%", "Feb", "2005", "10.00%", "0...

[ [ 108, 90, 221, 137 ], [ 234, 89, 351, 138 ], [ 362, 89, 411, 138 ], [ 417, 89, 516, 138 ], [ 106, 197, 156, 220 ], [ 160, 196, 195, 220 ], [ 198, 196, 247, 220 ], [ 250, ...

what is Actos TRx (000s) in the year 2003 ?

9,497

575

[ "Most", "Significant", "Adverse", "Events", "Risks", "for", "Pioglitazone", "Risk", "Onset", "Reversibility", "Clinical", "Findings", "Occurrence", "of", "ALT", "Elevation", "Within", "2", "months", "Only", "through", "Drug", "Placebo", "Liver", "Failure", "Transpla...

[ [ 246, 181, 293, 198 ], [ 297, 181, 392, 198 ], [ 396, 182, 469, 199 ], [ 473, 182, 534, 199 ], [ 538, 182, 588, 199 ], [ 593, 182, 618, 199 ], [ 622, 182, 735, 199 ], [ 25...

how much percent of drug quantity present in rezulin under the title of 'clinical findings'?

1.7%

584

[ "Actos", "Share", "of", "TZDs", "Retail", "TRX", "SOM,", "IMS", "Health", "60.00%", "Actual", "Forecast", "50.00%", "40.00%", "Launch", "of", "Launch", "of", "30.00%", "Merck's", "BMS'", "PPAR's", "PPAR's", "Q3", "2005", "20.00%", "Feb", "2005", "10.00%", "0...

[ [ 108, 90, 221, 137 ], [ 234, 89, 351, 138 ], [ 362, 89, 411, 138 ], [ 417, 89, 516, 138 ], [ 106, 197, 156, 220 ], [ 160, 196, 195, 220 ], [ 198, 196, 247, 220 ], [ 250, ...

what is the percentage of plan TZD share in the year 2004 ?

42.9%

575

[ "Most", "Significant", "Adverse", "Events", "Risks", "for", "Pioglitazone", "Risk", "Onset", "Reversibility", "Clinical", "Findings", "Occurrence", "of", "ALT", "Elevation", "Within", "2", "months", "Only", "through", "Drug", "Placebo", "Liver", "Failure", "Transpla...

[ [ 246, 181, 293, 198 ], [ 297, 181, 392, 198 ], [ 396, 182, 469, 199 ], [ 473, 182, 534, 199 ], [ 538, 182, 588, 199 ], [ 593, 182, 618, 199 ], [ 622, 182, 735, 199 ], [ 25...

how much percent of placebo present in avandia alongside of the clinical findings?

0.20%

584

[ "Actos", "Share", "of", "TZDs", "Retail", "TRX", "SOM,", "IMS", "Health", "60.00%", "Actual", "Forecast", "50.00%", "40.00%", "Launch", "of", "Launch", "of", "30.00%", "Merck's", "BMS'", "PPAR's", "PPAR's", "Q3", "2005", "20.00%", "Feb", "2005", "10.00%", "0...

[ [ 108, 90, 221, 137 ], [ 234, 89, 351, 138 ], [ 362, 89, 411, 138 ], [ 417, 89, 516, 138 ], [ 106, 197, 156, 220 ], [ 160, 196, 195, 220 ], [ 198, 196, 247, 220 ], [ 250, ...

in which month and the year the launch of Merck's PPAR's took place?

FEB 2005

584

[ "Actos", "Share", "of", "TZDs", "Retail", "TRX", "SOM,", "IMS", "Health", "60.00%", "Actual", "Forecast", "50.00%", "40.00%", "Launch", "of", "Launch", "of", "30.00%", "Merck's", "BMS'", "PPAR's", "PPAR's", "Q3", "2005", "20.00%", "Feb", "2005", "10.00%", "0...

[ [ 108, 90, 221, 137 ], [ 234, 89, 351, 138 ], [ 362, 89, 411, 138 ], [ 417, 89, 516, 138 ], [ 106, 197, 156, 220 ], [ 160, 196, 195, 220 ], [ 198, 196, 247, 220 ], [ 250, ...

what is the TZD's TRx (000s) in the year 2005 ?

22,902

575

[ "Most", "Significant", "Adverse", "Events", "Risks", "for", "Pioglitazone", "Risk", "Onset", "Reversibility", "Clinical", "Findings", "Occurrence", "of", "ALT", "Elevation", "Within", "2", "months", "Only", "through", "Drug", "Placebo", "Liver", "Failure", "Transpla...

[ [ 246, 181, 293, 198 ], [ 297, 181, 392, 198 ], [ 396, 182, 469, 199 ], [ 473, 182, 534, 199 ], [ 538, 182, 588, 199 ], [ 593, 182, 618, 199 ], [ 622, 182, 735, 199 ], [ 25...

what is the total number of all claims under the title of "summary of litigation risk in the ous territories"?

10

585

[ "Strategic", "Intent", "&", "CSFs", "Strategic", "Intent:", "Establish", "Actos", "as", "the", "best", "OAD", "medication", "by", "treating", "insulin", "resistance,", "through", "sustained", "glycemic", "control", "and", "reduced", "cardiovascular", "risk.", "Criti...

[ [ 95, 114, 262, 168 ], [ 270, 113, 386, 168 ], [ 393, 113, 419, 165 ], [ 429, 113, 527, 163 ], [ 86, 224, 205, 261 ], [ 210, 224, 297, 261 ], [ 102, 306, 217, 341 ], [ 222,...

what is the first TZD used for type 2 patients ?

ACTOS

585

[ "Strategic", "Intent", "&", "CSFs", "Strategic", "Intent:", "Establish", "Actos", "as", "the", "best", "OAD", "medication", "by", "treating", "insulin", "resistance,", "through", "sustained", "glycemic", "control", "and", "reduced", "cardiovascular", "risk.", "Criti...

[ [ 95, 114, 262, 168 ], [ 270, 113, 386, 168 ], [ 393, 113, 419, 165 ], [ 429, 113, 527, 163 ], [ 86, 224, 205, 261 ], [ 210, 224, 297, 261 ], [ 102, 306, 217, 341 ], [ 222,...

For which type of diabetes the TZD's prescribed earlier in treatment?

Type 2 diabetes

585

[ "Strategic", "Intent", "&", "CSFs", "Strategic", "Intent:", "Establish", "Actos", "as", "the", "best", "OAD", "medication", "by", "treating", "insulin", "resistance,", "through", "sustained", "glycemic", "control", "and", "reduced", "cardiovascular", "risk.", "Criti...

[ [ 95, 114, 262, 168 ], [ 270, 113, 386, 168 ], [ 393, 113, 419, 165 ], [ 429, 113, 527, 163 ], [ 86, 224, 205, 261 ], [ 210, 224, 297, 261 ], [ 102, 306, 217, 341 ], [ 222,...

what has to be establish as the the best OAD medication by treating insulin resistance ?

ACTOS